<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children - McNicol, ED - 2016 | Cochrane Library</title> <meta content="Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children - McNicol, ED - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006883.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children - McNicol, ED - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006883.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006883.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children" name="citation_title"/> <meta content="Ewan D McNicol" name="citation_author"/> <meta content="ewan.mcnicol@tufts.edu" name="citation_author_email"/> <meta content="Aikaterini Tzortzopoulou" name="citation_author"/> <meta content="Tufts Medical Center" name="citation_author_institution"/> <meta content="Roman Schumann" name="citation_author"/> <meta content="Tufts Medical Center" name="citation_author_institution"/> <meta content="Daniel B Carr" name="citation_author"/> <meta content="Tufts University School of Medicine" name="citation_author_institution"/> <meta content="Aman Kalra" name="citation_author"/> <meta content="Tufts Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD006883.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/09/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006883.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006883.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006883.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antifibrinolytic Agents [*therapeutic use]; Blood Loss, Surgical [*prevention &amp; control]; Blood Transfusion [statistics &amp; numerical data]; Randomized Controlled Trials as Topic; Scoliosis [*surgery]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006883.pub3&amp;doi=10.1002/14651858.CD006883.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="tkZQC4GK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006883\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006883\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","pl","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006883.pub3",title:"Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children",firstPublishedDate:"Sep 19, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Anaesthesia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006883.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006883.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006883.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006883.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006883.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006883.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006883.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006883.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006883.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006883.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2088 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006883.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-sec-0089"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-sec-0081"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/appendices#CD006883-sec-0094"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/table_n/CD006883StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/table_n/CD006883StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/information#CD006883-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Ewan D McNicol</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/information#CD006883-cr-0003">Aikaterini Tzortzopoulou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/information#CD006883-cr-0004">Roman Schumann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/information#CD006883-cr-0005">Daniel B Carr</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006883.pub3/information#CD006883-cr-0006">Aman Kalra</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/information/en#CD006883-sec-0104">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 September 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006883.pub3">https://doi.org/10.1002/14651858.CD006883.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006883-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006883-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006883-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006883-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006883-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006883-abs-0001" lang="en"> <section id="CD006883-sec-0001"> <h3 class="title" id="CD006883-sec-0001">Background</h3> <p>This is an updated version of the original Cochrane review first published in 2008. Scoliosis surgery is often associated with substantial blood loss and potentially detrimental effects in children. Antifibrinolytic agents are often used to reduce perioperative blood loss. Clinical trials have evaluated their efficacy in children undergoing surgical correction of scoliosis, but no systematic review has been published. This review was first published in 2008 and was updated in 2016. </p> </section> <section id="CD006883-sec-0002"> <h3 class="title" id="CD006883-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of aprotinin, tranexamic acid and aminocaproic acid in reducing blood loss and transfusion requirements in children undergoing surgery for correction of idiopathic or secondary scoliosis. </p> </section> <section id="CD006883-sec-0003"> <h3 class="title" id="CD006883-sec-0003">Search methods</h3> <p>We ran the search for the previous review in June 2007. For this updated version, we searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 7), MEDLINE (1946 to August week 1 2015), Embase (1947 to 2015 week 38), Latin American Caribbean Health Sciences Literature (LILACS) (1982 to 14 August 2015), Database of Abstracts of Reviews of Effects (DARE; 2015, Issue 2) and reference lists of reviews and retrieved articles for randomized controlled trials in any language. We also checked the clinical trial registry at <a href="http://www.clinicaltrials.go" target="_blank">http://www.clinicaltrials.go</a>v on 8 October 2015. </p> </section> <section id="CD006883-sec-0004"> <h3 class="title" id="CD006883-sec-0004">Selection criteria</h3> <p>We included blinded and unblinded randomized controlled trials (RCTs) that evaluated the effects of antifibrinolytics on perioperative blood loss in children 18 years of age or younger and undergoing scoliosis surgery. </p> </section> <section id="CD006883-sec-0005"> <h3 class="title" id="CD006883-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data. The primary outcome was total blood loss (intraoperative and postoperative combined). Secondary efficacy outcomes were the number of participants receiving blood transfusion (both autologous and allogeneic) or receiving allogeneic blood transfusion alone, and the total amount of blood transfused. Safety outcomes included the number of deaths, the number of participants reporting any adverse event or a serious adverse event, withdrawals due to adverse events and the number of participants experiencing a specific adverse event (i.e. renal insufficiency, hypersensitivity or thrombosis). We assessed methodological risk of bias for each included study and employed the GRADE approach to assess the overall quality of the evidence. </p> </section> <section id="CD006883-sec-0006"> <h3 class="title" id="CD006883-sec-0006">Main results</h3> <p>We included three new studies (201 participants) in this updated review, for a total of nine studies (455 participants). All but one study employed placebo as the control group intervention. For the primary outcome, antifibrinolytic drugs decreased the amount of perioperative blood loss by 427 mL (95% confidence interval (CI) 251 to 603 mL), for a reduction of over 20% versus placebo. We rated the quality of evidence for our primary outcome as low on the basis of unclear risk of bias for several domains in most studies and the small total number of participants. </p> <p>For secondary outcomes, fewer participants receiving antifibrinolytic drugs received transfusion (allogeneic or autologous) versus those receiving placebo (risk ratio (RR) 0.65, 95% CI 0.50 to 0.85, number needed to treat to prevent one additional harmful outcome (NNTp) 5; very low‐quality evidence). Only two studies specifically evaluated the number of participants transfused with only allogeneic blood (risk difference (RD) ‐0.15, 95% CI ‐0.26 to ‐0.03, NNTp 7; very low‐quality evidence). Antifibrinolytic drugs decreased the volume of blood transfused by 327 mL (95% CI ‐186 to ‐469 mL; low‐quality evidence). </p> <p>No study reported deaths in active or control groups. Data were insufficient to allow performance of meta‐analysis for any safety outcome. No studies adequately described their methods in assessing safety. The only adverse event of note occurred in one study, when three participants in the placebo group developed postoperative deep vein thrombosis. </p> </section> <section id="CD006883-sec-0007"> <h3 class="title" id="CD006883-sec-0007">Authors' conclusions</h3> <p>Since the last published version of this review (2008), we have found three new studies. Additional evidence shows that antifibrinolytics reduce the requirement for both autologous and allogeneic blood transfusion. Limited evidence of low to very low quality supports the use of antifibrinolytic drugs for reducing blood loss and decreasing the risk, and volume, of transfusion in children undergoing scoliosis surgery. Evidence is insufficient to support the use of a particular agent, although tranexamic acid may be preferred, given its widespread availability. The optimal dose regimen for any of these three agents has not been established. Although adverse events appear to occur infrequently, evidence is insufficient to confirm the safety of these agents, particularly for rare but potentially catastrophic events. No long‐term safety data are available. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006883-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006883-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006883-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006883-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006883-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/pl#CD006883-abs-0006">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006883-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006883-abs-0004" lang="en"> <h3>Antifibrinolytic agents to reduce blood loss in the surgical correction of scoliosis (abnormal curvatures of the spine) in children </h3> <p><b>Background</b> </p> <p>Scoliosis is a curving of the spine beyond that which is normal. Surgery may be needed to correct scoliosis and is often carried out when the child is young. Substantial bleeding may occur during surgery and can lead to serious complications, such as multiple organ failure. Many methods are used to reduce blood loss, including drugs that modify clotting pathways in the body. Medications known as antifibrinolytic drugs can reduce bleeding by preventing the breakdown of a blood clot. This review is an update of a review published in 2008, which looked at how well these drugs work, and how safe they are. </p> <p><b>Search date</b> </p> <p>This review is an update of a review that we first published in 2008. Our latest search for articles took place in August 2015. </p> <p><b>Study characteristics</b> </p> <p>The antifibrinolytic drugs evaluated in this systematic review were aprotinin, tranexamic acid and aminocaproic acid. We found nine studies that enrolled a total of 455 participants, aged 18 years or younger, who received either antifibrinolytic drugs or a placebo. </p> <p>Total enrolment in each study ranged from 36 participants to 80 participants. Two of the studies evaluated aprotinin, four tranexamic acid and four aminocaproic acid. One study compared aminocaproic acid with tranexamic acid. The other studies administered placebo to the control group. Studies that evaluated aprotinin and aminocaproic acid used high doses (when reported). Of the studies that evaluated tranexamic acid, two used high doses, one used low doses and one did not describe the dose given. Five studies evaluated idiopathic scoliosis (scoliosis with no known cause), and four evaluated both idiopathic scoliosis and scoliosis that occurred as the result of another disease, such as cerebral palsy. </p> <p>Of the nine included studies, five reported how long patients were assessed. Follow‐up ranged from one to 10 days after surgery, or lasted for the participant's length of stay in the hospital. </p> <p><b>Study funding sources</b> </p> <p>Two studies received grants from organizations of healthcare professionals, and one was sponsored by a pharmaceutical company. The remaining studies did not report sources of funding. </p> <p><b>Key results</b> </p> <p>Antifibrinolytic drugs reduced the amount of blood lost during, or immediately after, surgery, by 427 millilitres (mL) (more than a 20% reduction in blood loss) and the amount of blood transfused during the same period by 327 mL. The number of children who received transfusions, either through blood from a donor or through a combination of blood from a donor and their own saved blood, was also significantly decreased. We assessed the quality of the evidence for all of these findings as low or very low because of the small numbers of participants, some concerns about study designs and imprecision in study findings. </p> <p>No children included in any studies died, and very few adverse events were reported, although three children receiving placebo in one study developed a clot. However, these studies may not have adequately looked for adverse events, or study authors might not have reported them fully. Also, the number of children evaluated was too small and the time of follow‐up too short to allow review authors to draw any conclusions about their safety. </p> <p><b>Conclusion</b> </p> <p>This systematic review showed that antifibrinolytic drugs reduce blood loss and decrease the number of children receiving blood transfusions and the amount of blood transfused, but the evidence supporting any of these findings is not very strong. The safety of antifibrinolytic drugs remains unclear. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006883-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006883-sec-0089"></div> <h3 class="title" id="CD006883-sec-0090">Implications for practice</h3> <section id="CD006883-sec-0090"> <p>Since the last version of this review, additional evidence has demonstrated that antifibrinolytics reduce the requirement for both autologous and allogeneic blood transfusion. Limited evidence of low to very low quality supports the use of antifibrinolytic drugs for reducing blood loss and risk for, and volume of, transfusion in children undergoing scoliosis surgery. Evidence is insufficient to support the use of a particular agent, although tranexamic acid may be preferred, given its widespread availability. The optimal dose regimen for any of these three agents has not been established. Although adverse events appear to occur infrequently, evidence is insufficient to confirm the safety of these agents, particularly for rare but potentially catastrophic events. No long‐term safety data are available. </p> </section> <h3 class="title" id="CD006883-sec-0091">Implications for research</h3> <section id="CD006883-sec-0091"> <p>Evidence demonstrating reduced blood loss and less requirement for transfusion is based on very limited numbers of participants and is susceptible to publication bias. Therefore, larger studies are required to increase the robustness of our findings. Future studies should assess head‐to‐head comparisons of different antifibrinolytic drugs to identify any differences in effectiveness or safety. Studies should also enrol more patients with secondary scoliosis and should report results separately for this population. Optimal dosing regimens have not been established; studies employing different regimens for the same agent will help to clarify this question. Although challenging, we also recommend that the long‐term safety of antifibrinolytic drugs in children should be evaluated in view of safety concerns with some antifibrinolytic drugs when used in adults. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006883-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006883-sec-0022"></div> <div class="table" id="CD006883-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Mean total blood loss (mL)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antifibrinolytics compared with placebo or each other for children undergoing surgery for scoliosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children undergoing surgery for scoliosis<br/> <b>Settings:</b> children's hospitals in the USA and Canada<br/> <b>Intervention:</b> antifibrinolytics<br/> <b>Comparison:</b> placebo or each other </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo or each other</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood loss (mL: antifibrinolytics vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood loss (mL): antifibrinolytics vs placebo in the intervention groups was<br/> <b>426.56 lower</b> <br/> (602.59 to 250.53 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood loss (mL): aminocaproic acid vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood loss (mL): aminocaproic acid vs placebo in the intervention groups was<br/> <b>325 lower</b> <br/> (586.83 to 63.17 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood loss (mL): aprotinin vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood loss (mL): aprotinin vs placebo in the intervention groups was<br/> <b>450.41 lower</b> <br/> (726.64 to 174.19 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood loss (mL): tranexamic acid vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood loss (mL): tranexamic acid vs placebo in the intervention groups was<br/> <b>681.81 lower</b> <br/> (1149.12 to 214.49 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood loss (mL): aminocaproic acid vs tranexamic acid</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood loss (mL): aminocaproic acid vs tranexamic acid in the intervention groups was<br/> <b>463 higher</b> <br/> (155.22 lower to 1081.22 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI = confidence interval. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Unclear or high risk of bias in &gt; 1 domain for each study.<br/> <sup>b</sup>Total population size is less than 400.<br/> <sup>c</sup>Wide confidence interval, which includes no effect AND appreciable harm. </p> <p>Quality of evidence downgraded by two levels for all outcomes.</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006883-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Number of participants receiving blood transfusion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antifibrinolytics compared with placebo for children undergoing surgery for scoliosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children undergoing surgery for scoliosis<br/> <b>Settings:</b> children's hospitals in the USA and Canada<br/> <b>Intervention:</b> antifibrinolytics<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants receiving blood transfusion: antifibrinolytics vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.65</b> <br/> (0.5 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>195<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>602 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>391 per 1000</b> <br/> (301 to 512) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>464 per 1000</b> <br/> (357 to 607) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants receiving blood transfusion: aminocaproic acid vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.48</b> <br/> (0.3 to 0.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>108<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>490 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>235 per 1000</b> <br/> (147 to 372) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>554 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>266 per 1000</b> <br/> (166 to 421) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants receiving blood transfusion: aprotinin vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.75</b> <br/> (0.44 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>43<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a,b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>536 per 1000</b> <br/> (314 to 907) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>536 per 1000</b> <br/> (314 to 907) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants receiving blood transfusion: tranexamic acid vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.85</b> <br/> (0.56 to 1.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>44<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a,b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>607 per 1000</b> <br/> (400 to 929) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>607 per 1000</b> <br/> (400 to 928) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI = confidence interval; RR = risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Unclear or high risk of bias for &gt; 1 domain for each study.<br/> <sup>b</sup>Total number of events is less than 300.<br/> <sup>c</sup>Susceptible to publication bias.<br/> <sup>d</sup>Large differences in effect between studies.<br/> <sup>e</sup>Wide confidence interval, which includes no effect AND benefit. </p> <p>Quality of evidence downgraded by three levels for all outcomes.</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006883-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Number of participants receiving transfusion with allogeneic blood</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antifibrinolytics compared with placebo for children undergoing surgery for scoliosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children undergoing surgery for scoliosis<br/> <b>Settings:</b> children's hospitals in the USA and Canada<br/> <b>Intervention:</b> antifibrinolytics<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants receiving transfusion with allogeneic blood: antifibrinolytics vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.11</b> <br/> (0.01 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>79<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> <br/> (2 to 308) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> <br/> (1 to 247) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants receiving transfusion with allogeneic blood: aminocaproic acid vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative risk not estimable as no events occurred in either group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants receiving transfusion with allogeneic blood: aprotinin vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.11</b> <br/> (0.01 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>43<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> <br/> (3 to 494) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> <br/> (3 to 495) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI = confidence interval; RR = risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Unclear or high risk of bias for &gt; 1 domain for each study.<br/> <sup>b</sup>Unexplained heterogeneity.<br/> <sup>c</sup>Total number of events is less than 300.<br/> <sup>d</sup>Wide confidence interval, which includes no effect AND benefit. </p> <p>Quality of evidence downgraded by three levels for all outcomes.</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006883-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Mean total volume of blood transfused (mL)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antifibrinolytics compared with placebo for children undergoing surgery for scoliosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children undergoing surgery for scoliosis<br/> <b>Settings:</b> children's hospitals in the USA and Canada<br/> <b>Intervention:</b> antifibrinolytics<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood transfused (mL): antifibrinolytics vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood transfused (mL): antifibrinolytics vs placebo in the intervention groups was<br/> <b>327.41 lower</b> <br/> (469.04 to 185.78 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood transfused (mL): aminocaproic acid vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood transfused (mL): aminocaproic acid vs placebo in the intervention groups was<br/> <b>245 lower</b> <br/> (481.03 to 8.97 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood transfused (mL): aprotinin vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood transfused (mL): aprotinin vs placebo in the intervention groups was<br/> <b>361.42 lower</b> <br/> (583.88 to 138.96 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood transfused (mL): tranexamic acid vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood transfused (mL): tranexamic acid vs placebo in the intervention groups was<br/> <b>395.14 lower</b> <br/> (687.55 to 102.73 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI = confidence interval. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Unclear risk of bias for &gt; 1 domain in most studies<br/> <sup>b</sup>Total population size is less than 400 </p> <p>Quality of evidence downgraded by two levels for all outcomes</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006883-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006883-sec-0023"></div> <p>This review is an update of a review previously published in the <i>Cochrane Database of Systematic Reviews</i> on antifibrinolytic agents for reducing blood loss in scoliosis surgery in children (<a href="./references#CD006883-bbs2-0083" title="TzortzopoulouA , CepedaMS , SchumannR , CarrDB . Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006883.pub2] ">Tzortzopoulou 2008b</a>). </p> <section id="CD006883-sec-0024"> <h3 class="title" id="CD006883-sec-0024">Description of the condition</h3> <p>Scoliosis is a complex lateral and rotational deformity of the thoracolumbar spine (<a href="./references#CD006883-bbs2-0040" title="El‐HawaryR , ChukwunyerenwaC . Update on evaluation and treatment of scoliosis. Pediatric Clinics of North America2014;61:1223‐41. ">El‐Hawary 2014</a>). It may be primary and idiopathic, which implies an unknown origin, although with a probable genetic basis, or secondary owing to congenital, neurological or musculoskeletal disorders. On the basis of age of onset, idiopathic scoliosis is further subdivided into infantile (children aged three years and younger), juvenile (children three to ten years old) and adolescent (older than 10 years to 18 years old). It may be further subclassified as early (before five years of age) or late onset (after five years of age), given that the natural history, rate of occurrence and approaches to treatment for patients younger than five years of age differ from those for patients older than five years. Idiopathic scoliosis accounts for 80% of all cases. In contrast to secondary scoliosis, idiopathic scoliosis may occur in otherwise healthy individuals (<a href="./references#CD006883-bbs2-0060" title="NegriniS , AulisaL , FerraroC , FraschiniP , MasieroS , SimonazziP , et al. Italian guidelines on rehabilitation treatment of adolescents with scoliosis OR other spinal deformities. European Mediphysica2005;41:183‐201. [MEDLINE: 16200035] ">Negrini 2005</a>). </p> <p>The prognosis of scoliosis is related to its origin and speed of progression. The prognosis is improved when treated early, while deformities are still mild, and before secondary deformities are established (<a href="./references#CD006883-bbs2-0075" title="ThomsenM , AbelR . Imaging in scoliosis from the orthopaedic surgeon's point of view. European Journal of Radiology2006;58(1):41‐7. [MEDLINE: 16439089] ">Thomsen 2006</a>). The degree of deformity determines the optimal approach to treatment (<a href="./references#CD006883-bbs2-0040" title="El‐HawaryR , ChukwunyerenwaC . Update on evaluation and treatment of scoliosis. Pediatric Clinics of North America2014;61:1223‐41. ">El‐Hawary 2014</a>). Observation is recommended for patients with a Cobb angle (a measure of severity of spinal deformity) of 25º or less, and a brace is recommended for patients with curves between 25º and 45º; surgery is generally reserved for patients with curvature greater than 50º in the thoracic spine or 40º in the lumbar spine, and for those in whom scoliosis is progressing. Uncorrected, scoliosis results in curve progression, cosmetic deformity, back pain and respiratory compromise. The aims of surgical intervention are to prevent progression, improve posture and back pain and prevent further deterioration of restrictive lung defects. </p> <p>Despite great improvements in the surgical techniques used to treat patients with scoliosis, these are frequently lengthy operations with substantial blood loss that can lead to serious adverse events. Factors influencing blood loss include neuromuscular origin of scoliosis, platelet dysfunction, poor nutritional status, severity of scoliosis, poor vascular vasoconstrictive response, increased bleeding time and fibrinolysis (<a href="./references#CD006883-bbs2-0033" title="BrennBR , TherouxMC , DabneyKW , MillerF . Clotting parameters and thromboelastography in children with neuromuscular and idiopathic scoliosis undergoing posterior spinal fusion. Spine2004;29:E310‐4. ">Brenn 2004</a>; <a href="./references#CD006883-bbs2-0043" title="FievezE , Schultze‐BalinC , HerbauxB , DalmasS , ScherpereelP . A study of blood loss during surgery for scoliosis. Posterior approach in 319 adolescents [Etude du saignement dans la chirurgie de la scoliose. Interventions par voie posterieure chez 319 adolescents]. Cahiers d'Anesthesiologie1995;43(5):425‐33. [MEDLINE: 8564665] ">Fievez 1995</a>; <a href="./references#CD006883-bbs2-0044" title="ForstJ , ForstR , LeitheH , MaurinN . Platelet function deficiency in Duchenne muscular dystrophy. Neuromuscular Disorders1998;8(1):46‐9. [MEDLINE: 9565990] ">Forst 1998</a>; <a href="./references#CD006883-bbs2-0057" title="MeertKL , KannanS , MooneyJF . Predictors of red cell transfusion in children and adolescents undergoing spinal fusion surgery. Spine2002;27(19):2137‐42. [MEDLINE: 12394928] ">Meert 2002</a>; <a href="./references#CD006883-bbs2-0062" title="NoordeenMH , HaddadFS , MuntoniF , GobbiP , HollyerJS , BentleyG . Blood loss in Duchenne muscular dystrophy: vascular smooth muscle dysfunction?. Journal of Pediatric Orthopaedics, Part B1999;8(3):212‐5. [MEDLINE: 10399127] ">Noordeen 1999</a>; <a href="./references#CD006883-bbs2-0076" title="TurturroF , RoccaB , GuminaS , DeCristofaroR , MangiolaF , MaggianoN , et al. Impaired primary hemostasis with normal platelet function in Duchenne muscular dystrophy during highly‐invasive spinal surgery. Neuromuscular Disorders2005;15(8):532‐40. [MEDLINE: 16009551] ">Turturro 2005</a>). Secondary scoliosis is frequently a result of neuromuscular disorders such as spina bifida, spastic cerebral palsy and spinal muscular dystrophy. Many of these patients have learning and intellectual disabilities, impaired gross motor dexterity, swallowing difficulties, incontinence, chronic infections and overall poor nutritional status. Anaemia is thus very common in this population. No evidence suggests that patients with cerebral palsy have coagulopathy and platelet dysfunction. Overall, clinically, these patients have a poor baseline health status, reduced physiological reserve and healing capacity and a greater propensity for perioperative bleeding (<a href="./references#CD006883-bbs2-0052" title="LeeSY , SohnHM , ChungCY , DoSH , LeeKM , KwonSS , et al. Perioperative complications of orthopedic surgery for lower extremity in patients with cerebral palsy. Journal of Korean Medical Science2015;30:489‐94. ">Lee 2015</a>; <a href="./references#CD006883-bbs2-0064" title="ReillyS , SkuseD , PobleteX . Prevalence of feeding problems and oral motor dysfunction in children with cerebral palsy: a community survey. Journal of Pediatrics1996;129:877‐82. ">Reilly 1996</a>; <a href="./references#CD006883-bbs2-0077" title="WassCT , WarnerME , WorrellGA , CastagnoJA , HoweM , KerberKA , et al. Effect of general anesthesia in patients with cerebral palsy at the turn of the new millennium: a population‐based study evaluating perioperative outcome and brief overview of anesthetic implications of this coexisting disease. Journal of Child Neurology2012;27:859‐66. ">Wass 2012</a>). </p> <p>Substantial blood loss mandates volume repletion with crystalloid, colloid or blood products. Infusion of intravenous fluids for blood replacement following massive bleeding can lead to hypothermia and haemodilution. Haemodilution dilutes haemoglobin as well as coagulation factors; this leads to worsened surgical bleeding (<a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>), attenuated oxygen transport to tissues and acid‐base balance disorders. Blood transfused may be allogeneic (from another donor) or autologous (donated by the patient before surgery). Allogeneic blood transfusions are associated with risk of infection from the donor and from microbial contamination introduced during blood processing, allergic reactions, volume overload and immunosuppression (<a href="./references#CD006883-bbs2-0053" title="LubanN . Transfusion safety: where are we today?. Annals of the New York Academy of Sciences2005;1054:325‐41. [MEDLINE: 16339681] ">Luban 2005</a>; <a href="./references#CD006883-bbs2-0067" title="RobackJD , SuL , ZimringJC , HillyerCD . Transfusion‐transmitted cytomegalovirus: lessons from a murine model. Transfusion Medicine Reviews2007;21(1):26‐36. [MEDLINE: 17174218] ">Roback 2007</a>). Although autologous transfusion is associated with less risk of infection, other factors such as venous access, distress from the pain of multiple venipunctures, delay of surgery to allow blood collection and regeneration and low preoperative haematocrit levels hinder or limit the collection of autologous blood from children (<a href="./references#CD006883-bbs2-0031" title="BookeM , ReichA . Autotransfusion and blood‐sparing techniques in infants and children. Review article. Current Opinion in Anaesthesiology2000;13(3):303‐6. [MEDLINE: 17016319] ">Booke 2000</a>; <a href="./references#CD006883-bbs2-0055" title="MayerMN , deMontalembertM , AudatF , BrussetMC , HoufaniB , MerckxJ , et al. Autologous blood donation for elective surgery in children weighing 8‐25 kg. Vox Sanguinis1996;70(4):224‐8. [MEDLINE: 9123928] ">Mayer 1996</a>; <a href="./references#CD006883-bbs2-0058" title="MezrowCK , BergsteinI , TartterPI . Postoperative infections following autologous and homologous blood transfusions. Transfusion1992;32(1):27. [MEDLINE: 1731432] ">Mezrow 1992</a>; <a href="./references#CD006883-bbs2-0074" title="TakemuraM , OsugiH , TakadaN , KinoshitaH , HigashinoM . Immunologic effects of allogeneic versus autologous blood transfusion in patients undergoing radical oesophagectomy. European Surgical Research2003;35:115‐22. [MEDLINE: 12679622] ">Takemura 2003</a>; <a href="./references#CD006883-bbs2-0078" title="WeberTP , Grosse HartlageMA , VanAkenH , BookeM . Anaesthetic strategies to reduce perioperative blood loss in paediatric surgery. European Journal of Anaesthesiology2003;20(3):175‐81. [MEDLINE: 12650487] ">Weber 2003</a>). Additional methods to reduce the need for allogeneic blood transfusion include intraoperative "cell saving" and methods that decrease intraoperative bleeding such as acute normovolemic haemodilution, controlled hypotension, maintenance of low intrathoracic and intra‐abdominal pressure, infiltration of local vasoconstrictors and administration of systemic drugs such as desmopressin, recombinant factor VIIa and antifibrinolytics (<a href="./references#CD006883-bbs2-0034" title="CardoneD , KleinAA . Perioperative blood conservation. European Journal of Anaesthesiology2009;26:722‐9. ">Cardone 2009</a>). Intraoperative cell saving refers to autotransfusion of shed blood. This is accomplished with blood processing devices that aspirate, anticoagulate, wash and re‐infuse the cell suspension to the patient; or that directly re‐infuse unwashed filtered blood (<a href="./references#CD006883-bbs2-0035" title="CarrierM , DenaultA , LavoieJ , PerraultLP . Randomized controlled trial of pericardial blood processing with a cell‐saving device on neurologic markers in elderly patients undergoing coronary artery bypass graft surgery. Annals of Thoracic Surgery2006;82(1):51‐5. [MEDLINE: 16798186] ">Carrier 2006</a>;<a href="./references#CD006883-bbs2-0050" title="HuetC , SalmiLR , FergussonD , Koopman‐van GemertAW , RubensF , LaupacisA . A meta‐analysis of the effectiveness of cell salvage to minimize perioperative allogeneic blood transfusion in cardiac and orthopedic surgery. Anesthesia and Analgesia1999;89(4):861‐9. [MEDLINE: 10512256] ">Huet 1999</a>;<a href="./references#CD006883-bbs2-0051" title="JohnsonHD , MorganMS , UtleyJR , LeyandSA , Nguyen‐DuyT , CrawleyDM . Comparative analysis of recovery of cardiopulmonary bypass residual blood: cell saver vs. hemoconcentrator. Journal of Extra‐Corporeal Technology1994;26(4):194‐9. [MEDLINE: 10150684] ">Johnson 1994</a>;<a href="./references#CD006883-bbs2-0061" title="NiranjanG , AsimakopoulosG , KaragounisA , CockerillG , ThompsonM , ChandrasekaranV . Effects of cell saver autologous blood transfusion on blood loss and homologous blood transfusion requirements in patients undergoing cardiac surgery on‐ versus off‐cardiopulmonary bypass: a randomised trial. European Journal of Cardio‐Thoracic Surgery2006;30(2):271‐7. ">Niranjan 2006</a>). Acute normovolemic haemodilution refers to the rapid removal of the patient's own blood right before surgery and its preoperative replacement with crystalloid or colloid to maintain normovolaemia. This blood can then be re‐infused intraoperatively or postoperatively as needed (<a href="./references#CD006883-bbs2-0046" title="GreerJP , FoersterJ , LukensJN , RodgersGM , ParaskevasF , GladerB . Wintrobe's Clinical Hematology. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. [ISBN 0‐7817‐3650‐1] ">Greer 2004</a>; <a href="./references#CD006883-bbs2-0079" title="WeiskopfRB . Efficacy of acute normovolemic hemodilution assessed as a function of fraction of blood volume lost. Anesthesiology2001;94(3):439‐46. [11374603] ">Weiskopf 2001</a>). This approach is widely used in children to minimize the need for intraoperative allogeneic blood transfusion (<a href="./references#CD006883-bbs2-0047" title="GuayJ , deMoerlooseP , LasneD . Minimizing perioperative blood loss and transfusions in children. Canadian Journal of Anaesthesia2006;53 Suppl 6:59‐67. [MEDLINE: 16766791] ">Guay 2006</a>; <a href="./references#CD006883-bbs2-0069" title="SchallerRTJr , SchallerJ , FurmanEB , SchllerRT , SchallerL , FurmanEB . The advantages of hemodilution anesthesia for major liver resection in children. Journal of Pediatric Surgery1984;19(6):705‐10. [MEDLINE: 6097659] ">Schaller 1984</a>). Controlled hypotension (mean arterial pressure 30% lower than baseline) is not commonly used intraoperatively owing to the risk of hypoperfusion to vital organs including the spinal cord. Risk of ischaemic optic neuropathy is also increased. Appropriate patient selection and careful monitoring are vital for implementation of this technique (<a href="./references#CD006883-bbs2-0029" title="BarcelonaSL , ThompsonAA , CoteCJ . Intraoperative pediatric blood transfusion therapy: a review of common issues. Part II: transfusion therapy, special considerations, and reduction of allogenic blood transfusions. Paediatric Anaesthesia2005;15(10):814‐30. [MEDLINE: 16176309] ">Barcelona 2005</a>). Modified mechanical ventilatory parameters and correct positioning of the patient on supportive frames may help avoid excessive intrathoracic and intra‐abdominal pressures that would lead to impaired ventilation, reduced venous return and increased extradural vein volume with subsequent increased bleeding (<a href="./references#CD006883-bbs2-0063" title="RafiqueMB , StuthEA , TassoneJC . Increased blood loss during posterior spinal fusion for idiopathic scoliosis in an adolescent with Fontan physiology. Paediatric Anaesthesia2006;16(2):206‐12. [PUBMED: 16430422] ">Rafique 2006</a>; <a href="./references#CD006883-bbs2-0065" title="ReltonJE , ConnAW . Anaesthesia for the surgical correction by the Harrington method in children. Canadian Anaesthetists' Society Journal1963;10:603‐15. [PUBMED: 14076159] ">Relton 1963</a>; <a href="./references#CD006883-bbs2-0072" title="SolimanDE , MaslowAD , BokeschPM , StraffordM , KarlinL , RhodesJ , et al. Reports of investigation. Transesophageal echocardiography during scoliosis repair: comparison with CVP monitoring. Canadian Journal of Anaesthesiology1998;45(10):925‐32. ">Soliman 1998</a>). Infiltration of paraspinal muscles with agents such as adrenaline produces local vasoconstriction. The use of drugs such as desmopressin and antihaemophilic factors could, in theory, also decrease surgical bleeding by modifying the coagulation cascade (<a href="./references#CD006883-bbs2-0073" title="SzpalskiM , GunzburgR , SzternB . An overview of blood‐sparing techniques used in spine surgery during the perioperative period. European Spine Journal2004;Suppl 1:18‐27. [PUBMED: 15480823 ] ">Szpalski 2004</a>). Finally, the use of antifibrinolytics may reduce allogeneic transfusion requirements. </p> </section> <section id="CD006883-sec-0025"> <h3 class="title" id="CD006883-sec-0025">Description of the intervention</h3> <p>Antifibrinolytics reduce perioperative bleeding by inhibiting fibrin degradation. Fibrin provides the basic framework for formation of a blood clot (<a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>). The most commonly used antifibrinolytic drugs are aprotinin, tranexamic acid and aminocaproic acid. Aprotinin is a non‐specific serine protease inhibitor derived from bovine lung (<a href="./references#CD006883-bbs2-0081" title="ZuffereyP , MerquiolF , LaporteS , DecoususH , MismettiP , AuboyerC , et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?. Anesthesiology2006;105(5):1034‐46. [MEDLINE: 17065899] ">Zufferey 2006</a>). </p> </section> <section id="CD006883-sec-0026"> <h3 class="title" id="CD006883-sec-0026">How the intervention might work</h3> <p>Aprotinin, a serine protease inhibitor, has antifibrinolytic activity via direct inhibition of the plasmin and kinin‐kallikrein cascade (<a href="./references#CD006883-bbs2-0056" title="McCarthyMW , ColeyKC . Aprotinin for prophylaxis of blood loss. Annals of Pharmacotherapy1994;28(11):1246‐8. [MEDLINE: 7531517] ">McCarthy 1994</a>). Aprotinin has been shown to decrease blood loss in patients with increased risk of bleeding (<a href="./references#CD006883-bbs2-0070" title="ShigaT , WajimaZ , InoueT , SakamotoA . Aprotinin in major orthopedic surgery: a systematic review of randomized controlled trials. Anesthesia and Analgesia2005;101(6):1602‐7. [MEDLINE: 16301226] ">Shiga 2005</a>). Evidence from three observational studies and from a single randomized study, in patients undergoing cardiac surgery, show increased risk of perioperative renal dysfunction, cardiovascular events, pulmonary embolism and death with aprotinin, leading to its withdrawal from many national markets in 2007 (<a href="./references#CD006883-bbs2-0032" title="BremerichDH , StrametzR , KirchnerR , MoritzA , ZwisslerB . Aprotinin in cardiac surgery: more risks than usefulness?. German Anaesthesist2006;55(9):989‐2. [MEDLINE: 16874472] ">Bremerich 2006</a>; <a href="./references#CD006883-bbs2-0037" title="CooperJRJr , AbramsJ , FrazierOH , RadovancevicR , RadovancevicB , BraceyAW , et al. Fatal pulmonary microthrombi during surgical therapy for end‐stage heart failure. Journal of Thoracic and Cardiovascular Surgery2006;131(5):963‐8. [MEDLINE: 16678576] ">Cooper 2006</a>; <a href="./references#CD006883-bbs2-0042" title="U.S.Food , DrugAdministration . Early communication about an ongoing safety review aprotinin injection (marketed as Trasylol). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070281.htm. Accessed 5 September 2016. ">FDA 2007</a>; <a href="./references#CD006883-bbs2-0054" title="ManganoDT , MiaoY , VuylstekeA , TudorIC , JunejaR , FilipescuD , et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA2007;297(5):471‐9. [MEDLINE: 17284697] ">Mangano 2007</a>; <a href="./references#CD006883-bbs2-0068" title="RoystonD . The current place of aprotinin in the management of bleeding. Anaesthesia2015;70 (Suppl 1):46‐9. ">Royston 2015</a>). Although these data have been revisited and reanalyzed, bringing into question the findings of the four studies, aprotinin remains unavailable in many countries or has been given a restricted license for myocardial revascularization only (<a href="./references#CD006883-bbs2-0068" title="RoystonD . The current place of aprotinin in the management of bleeding. Anaesthesia2015;70 (Suppl 1):46‐9. ">Royston 2015</a>). Increased risk of mortality has not been demonstrated with the other antifibrinolytics. </p> <p>Tranexamic acid and epsilon‐aminocaproic acid (EACA) are synthetic lysine analogues that competitively inhibit activation of plasminogen to plasmin, a molecule responsible for the degradation of fibrin (<a href="./references#CD006883-bbs2-0048" title="HenryDA , CarlessPA , MoxeyAJ , O’ConnellD , StokesBJ , FergussonDA , et al. Anti‐fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD001886.pub4] ">Henry 2011</a>); comparative potency estimates vary (<a href="./references#CD006883-bbs2-0075" title="ThomsenM , AbelR . Imaging in scoliosis from the orthopaedic surgeon's point of view. European Journal of Radiology2006;58(1):41‐7. [MEDLINE: 16439089] ">Thomsen 2006</a>). </p> <p>Antifibrinolytic drugs are administered intravenously after induction of anaesthesia. Usually a loading dose is given over 15 to 20 minutes and is followed by continuous infusion. High doses appear to be more effective than low doses (<a href="./references#CD006883-bbs2-0048" title="HenryDA , CarlessPA , MoxeyAJ , O’ConnellD , StokesBJ , FergussonDA , et al. Anti‐fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD001886.pub4] ">Henry 2011</a>). </p> </section> <section id="CD006883-sec-0027"> <h3 class="title" id="CD006883-sec-0027">Why it is important to do this review</h3> <p>Systematic reviews of randomized controlled trials (RCTs) support the use of antifibrinolytic drugs to reduce perioperative blood loss in adults undergoing cardiac or orthopaedic surgery (<a href="./references#CD006883-bbs2-0027" title="ArnoldDM , FergussonDA , ChanA , CookR , FraserG , LimW , et al. Avoiding transfusions in children undergoing cardiac surgery: a meta‐analysis of randomized trials of aprotinin. Anesthesia and Analgesia2006;102:731‐7. [MEDLINE: 16492820] ">Arnold 2006</a>). Findings from cardiac surgery studies are not easily generalized to other types of surgery, such as scoliosis surgery, because use of heparin and extracorporeal bypass during cardiac surgery predisposes to bleeding. Clinical trials of administration of aprotinin (<a href="./references#CD006883-bbs2-0002" title="ColeJW , MurrayDJ , SniderRJ , BassettGS , BridwellKH , LenkeLG . Aprotinin reduces blood loss during spinal surgery in children. Spine2003;28(21):2482‐5. [MEDLINE: 14595168] ">Cole 2003</a>; <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>), tranexamic acid (<a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>) and aminocaproic acid (<a href="./references#CD006883-bbs2-0013" title="Florentino‐PinedaI , BlakemoreLC , ThompsonGH , Poe‐KochertC , AdlerP , TripiP . The effect of epsilon‐aminocaproic acid on perioperative blood loss in patients with idiopathic scoliosis undergoing posterior spinal fusion: a preliminary prospective study. Spine2001;26(10):1147‐51. [MEDLINE: 11413428] ">Florentino 2001</a>; <a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>; <a href="./references#CD006883-bbs2-0021" title="ThompsonGH , Florentino‐PinedaI , Poe‐KochertC . The role of Amicar in decreasing perioperative blood loss in idiopathic scoliosis. Spine2005;30:S94‐9. ">Thompson 2005</a>; <a href="./references#CD006883-bbs2-0022" title="ThompsonGH , Florentino‐PinedaI , ArmstrongDG , Poe‐KochertC . Fibrinogen levels following Amicar in surgery for idiopathic scoliosis. Spine2007;32:368‐72. [MEDLINE: 17268270] ">Thompson 2007</a>) have addressed their use in children undergoing surgical correction of scoliosis, but systematic reviews have not addressed this population. Additionally, evidence reveals extensive variation among dosage regimens in clinical practice, with no clear guidance on an optimal regimen for any single agent (<a href="./references#CD006883-bbs2-0030" title="BirdS , McGillN . Blood conservation and pain control in scoliosis corrective surgery: an online survey of UK practice. Paediatric Anaesthesia2011;21:50‐3. ">Bird 2011</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006883-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006883-sec-0028"></div> <p>To assess the efficacy and safety of aprotinin, tranexamic acid and aminocaproic acid in reducing blood loss and transfusion requirements in children undergoing surgery for correction of idiopathic or secondary scoliosis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006883-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006883-sec-0029"></div> <section id="CD006883-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006883-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included blinded and unblinded RCTs that evaluated the effects of antifibrinolytic drugs in reducing blood loss among children undergoing surgery for any type of scoliosis. We excluded studies that were not randomized and those that enrolled children and adults without providing separate reports on data derived from children. </p> </section> <section id="CD006883-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included studies that evaluated participants 18 years of age or younger who were undergoing surgery for correction of primary or secondary scoliosis. </p> </section> <section id="CD006883-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We included studies that evaluated aprotinin, tranexamic acid or aminocaproic acid given intravenously, immediately before or during scoliosis surgery, in comparison with placebo or with one another. </p> </section> <section id="CD006883-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>For the updated review, we kept the same efficacy outcomes (<a href="./references#CD006883-bbs2-0083" title="TzortzopoulouA , CepedaMS , SchumannR , CarrDB . Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006883.pub2] ">Tzortzopoulou 2008b</a>) but reassigned total blood loss as our primary outcome, as we considered this the most valid and clinically significant outcome for assessment of the efficacy of antifibrinolytic therapy. We now assigned all other outcomes as secondary. In the original review, our primary efficacy outcomes were mortality and number of participants requiring transfusion (<a href="./references#CD006883-bbs2-0083" title="TzortzopoulouA , CepedaMS , SchumannR , CarrDB . Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006883.pub2] ">Tzortzopoulou 2008b</a>), but we considered that the causes of mortality are multi‐factorial, and that requirements for transfusion differ among studies on the basis of thresholds determined by investigators. We added new safety outcomes, as listed below, to bring the review in line with current Cochrane methodological standards. These new safety outcomes required that we revisit the included studies from our original review to extract pertinent data. </p> <section id="CD006883-sec-0035"> <h5 class="title">Primary outcomes</h5> <section id="CD006883-sec-0036"> <h6 class="title">Mean total blood loss</h6> <p>We extracted the mean total blood loss in millilitres (mL) for each treatment arm. We merged intraoperative blood loss (which included the amount of blood salvaged by intraoperative cell saving) and postoperative blood loss (the amount of blood collected by suction drains) into mean total blood loss, so that we could calculate a pooled estimate from all included studies. </p> </section> </section> <section id="CD006883-sec-0037"> <h5 class="title">Secondary outcomes</h5> <p>Our secondary efficacy outcomes were:</p> <p> <ul id="CD006883-list-0001"> <li> <p>number of participants receiving transfusion with blood, whether autologous or allogeneic;</p> </li> <li> <p>number of participants receiving transfusion with allogeneic blood; and</p> </li> <li> <p>mean total amount of blood transfused (mL), including autologous and allogeneic.</p> </li> </ul> </p> <p>All outcomes included data from both time in the operating room and the postoperative period. We assumed that blood transfusions consisted of packed red blood cells, unless otherwise specified. </p> <p>Our safety outcomes were:</p> <p> <ul id="CD006883-list-0002"> <li> <p>number of deaths intraoperatively or at the end of the follow‐up period;</p> </li> <li> <p>number of participants reporting any adverse event (AE);</p> </li> <li> <p>number of participants experiencing a serious AE;</p> </li> <li> <p>number of participants withdrawing owing to an AE; and</p> </li> <li> <p>number of participants experiencing specific AEs (i.e. renal insufficiency, hypersensitivity or thrombotic events). </p> </li> </ul> </p> </section> </section> </section> <section id="CD006883-sec-0038"> <h3 class="title">Search methods for identification of studies</h3> <p>We ran the search for the original review on 20 June 2007 (<a href="./references#CD006883-bbs2-0083" title="TzortzopoulouA , CepedaMS , SchumannR , CarrDB . Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006883.pub2] ">Tzortzopoulou 2008b</a>) and subsequent searches on 14 August 2015. </p> <section id="CD006883-sec-0039"> <h4 class="title">Electronic searches</h4> <p>For this updated review, we searched the following databases.</p> <p> <ul id="CD006883-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 7).</p> </li> <li> <p>MEDLINE (OVID) (1946 to August week 1 2015).</p> </li> <li> <p>Embase (1947 to 2015 week 38).</p> </li> <li> <p>Latin American Caribbean Health Sciences Literature (LILACS) (1982 to 14 August 2015).</p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE; 2015, Issue 2).</p> </li> </ul> </p> <p>We have provided in the Appendices our updated search strategies for CENTRAL (<a href="./appendices#CD006883-sec-0095">Appendix 1</a>); MEDLINE (<a href="./appendices#CD006883-sec-0096">Appendix 2</a>); Embase (<a href="./appendices#CD006883-sec-0097">Appendix 3</a>); and LILACS (<a href="./appendices#CD006883-sec-0098">Appendix 4</a>). Search strategies included the following terms: aprotinin, tranexamic acid, aminocaproic acid, Trasylol, Cyclokapron, Amicar, antifibrinolytics, scoliosis surgery, idiopathic scoliosis, secondary scoliosis, spinal fusion and RCT filters. We applied no language restrictions. </p> </section> <section id="CD006883-sec-0040"> <h4 class="title">Searching other resources</h4> <p>For the original review, we searched the following conference proceedings (2003 to 2007): IARS (International Anesthesia Research Society), ASA (American Society of Anesthesiologists) and SRS (Scoliosis Research Society) (<a href="./references#CD006883-bbs2-0083" title="TzortzopoulouA , CepedaMS , SchumannR , CarrDB . Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006883.pub2] ">Tzortzopoulou 2008b</a>). For both the original review and the updated review, we also checked the reference lists of included studies and the clinical trial registry at <a href="http://www.clinicaltrials.gov" target="_blank">http://www.clinicaltrials.gov</a>, using the terms "aminocaproic acid", "aprotinin" and "tranexamic acid". Our last search took place on 8 October 2015. </p> <p>Again, we applied no language restrictions.</p> </section> </section> <section id="CD006883-sec-0041"> <h3 class="title" id="CD006883-sec-0041">Data collection and analysis</h3> <section id="CD006883-sec-0042"> <h4 class="title">Selection of studies</h4> <p>Two independent review authors screened each abstract identified in the electronic searches. We retrieved all articles in full when titles or abstracts referred to administration of any of the three antifibrinolytic agents during scoliosis surgery. </p> </section> <section id="CD006883-sec-0043"> <h4 class="title">Data extraction and management</h4> <p>We performed data extraction and analysis in duplicate. We resolved disagreements through discussion. If disagreement persisted, we sought agreement via consultation with a third review author (DC or RS). When studies did not provide sufficient data, we contacted study authors when possible. We performed all meta‐analyses using Review Manager 5.3.5 software (<a href="./references#CD006883-bbs2-0066" title="Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD006883-sec-0044"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For our earlier review (<a href="./references#CD006883-bbs2-0083" title="TzortzopoulouA , CepedaMS , SchumannR , CarrDB . Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006883.pub2] ">Tzortzopoulou 2008b</a>), we judged the quality of studies on the basis of method of randomization, method of allocation concealment, blinding of the study, completeness of follow‐up and use of an intention‐to‐treat analysis (see <a href="#CD006883-sec-0108">Differences between protocol and review</a>). </p> <p>For this updated review, two review authors independently assessed the risk of bias of all included studies by using a domain‐based evaluation, as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006883-bbs2-0049" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. www.cochrane‐handbook.org. Vol. 5.1.0, The Cochrane Collaboration, 2011. ">Higgins 2011</a>). We assessed the following for each study. </p> <p> <ul id="CD006883-list-0004"> <li> <p>Random sequence generation (selection bias). We assessed the method used to generate the allocation sequence as having low risk of bias (any truly random process, e.g. random number table; computer random number generator); high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); or unclear risk of bias (method not adequately described). </p> </li> <li> <p>Allocation concealment (selection bias). We assessed whether allocation could have been foreseen in advance of or during recruitment, or could have changed after assignment. We assessed these methods as having low risk of bias (e.g. telephone or central randomization; consecutively numbered sealed opaque envelopes); high risk of bias (open random allocation; unsealed or non‐opaque envelopes); or unclear risk of bias (method not adequately described). </p> </li> <li> <p>Blinding (detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We considered studies to be at low risk of bias if they stated that they were blinded and described the method used to achieve blinding (e.g. identical packaging; matched in appearance and colour), or at unclear risk if they stated that they were blinded but did not provide an adequate description of how this was achieved. We included unblinded studies and studies where authors did not mention blinding, and assessed these as having high risk of bias. </p> </li> <li> <p>Incomplete outcome data (attrition bias). We assessed the methods used to handle missing outcome data as having low risk of bias (e.g. no missing outcome data; reasons for missing outcome data unlikely to be related to true outcomes; missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups); high risk of bias (reasons for missing outcome data likely to be related to true outcomes, with imbalance in numbers or reasons for missing data across intervention groups; ‘as‐treated’ analysis done with substantial departure of the intervention received from that assigned at randomization); or unclear risk of bias (method not adequately described). </p> </li> <li> <p>Selective reporting (reporting bias). We assessed reporting of results as having low risk of bias (e.g. the study protocol was available and all of the study’s prespecified outcomes of interest in the review were reported in the prespecified way; the study protocol was not available but it is clear that published reports included all expected outcomes, including those that were prespecified); high risk of bias (e.g. not all of the study’s prespecified primary outcomes were reported; one or more primary outcomes were reported using measurements, analysis methods or subsets of data that were not prespecified); or unclear risk of bias (information insufficient to permit judgement of ‘low risk’ or ‘high risk’). </p> </li> </ul> </p> <p>For our updated review, we also assessed risk of bias due to sample size: Studies were considered to have low risk of bias if they included 200 or more participants per treatment arm; unclear risk if they included 50 to 199 participants per treatment arm; and high risk if they included fewer than 50 participants per treatment arm (<a href="./references#CD006883-bbs2-0039" title="DerryS , MooreRA . Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD004233.pub4] ">Derry 2012</a>). </p> </section> <section id="CD006883-sec-0045"> <h4 class="title">Measures of treatment effect</h4> <section id="CD006883-sec-0046"> <h5 class="title">Dichotomous data</h5> <p>We used discrete events, such as the number of participants receiving a blood transfusion or reporting AEs, to calculate the risk ratio (RR) or the risk difference (RD) or both, using Review Manager 5.3 software (<a href="./references#CD006883-bbs2-0066" title="Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). When a statistically significant risk difference was evident between interventions, we derived the number needed to treat for an additional beneficial outcome (NNTB) or an additional harmful outcome (NNTH), or the number needed to treat to prevent an additional harmful outcome (NNTp) (<a href="./references#CD006883-bbs2-0036" title="CookRJ , SackettDL . The number needed to treat: a clinically useful measure of treatment effect. BMJ1995;310:452‐4. ">Cook 1995</a>). We presented dichotomous outcomes in terms of both raw numbers and percentages of participants in each study arm benefiting from therapy or suffering AEs. </p> </section> <section id="CD006883-sec-0047"> <h5 class="title">Continuous data</h5> <p>We undertook meta‐analyses when comparable data were available from continuous outcomes (i.e. mean total blood loss or mean volume of blood transfused), using mean differences. </p> </section> </section> <section id="CD006883-sec-0048"> <h4 class="title">Unit of analysis issues</h4> <p>If two active treatment arms were compared with a placebo arm within the same meta‐analysis, we avoided double counting of participants in the placebo arm by splitting the total number between the active arms. However, this was not necessary in the current review. </p> </section> <section id="CD006883-sec-0049"> <h4 class="title">Dealing with missing data</h4> <p>When possible, we used intention‐to‐treat (ITT) analysis, whereby the ITT population consisted of participants who were randomized, received at least one dose of assigned study medication and provided at least one post‐baseline assessment. We assigned missing participants zero improvement. We looked for information about methods of imputation for missing data. </p> </section> <section id="CD006883-sec-0050"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity by visually examining forest plots and quantified this by using the I<sup>2</sup> statistic. The I<sup>2</sup> statistic is a reliable and robust test for quantifying heterogeneity because it does not depend on the number of trials nor on between‐study variance. The I<sup>2</sup> statistic measures the extent of inconsistency among study results, and can be interpreted as the proportion of total variation in study estimates that is due to heterogeneity rather than to sampling error. An I<sup>2</sup> statistical value greater than 50% is considered to indicate substantial heterogeneity (<a href="./references#CD006883-bbs2-0038" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Chichester: John Wiley &amp; Sons, 2011. ">Deeks 2011</a>). </p> </section> <section id="CD006883-sec-0051"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not attempt to investigate the likelihood that reporting bias occurred; however, for our updated review, we assessed the possible impact of publication bias using a method designed to detect the quantity of unpublished data with a null effect (relative benefit of one for relative risk) required to make any result clinically irrelevant (usually taken to mean an NNTB of 10 or higher; <a href="./references#CD006883-bbs2-0059" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24 [ISBN: 978‐0‐931092‐69‐5]. ">Moore 2008</a>). We defined the addition of four comparisons of typical size (400 participants in total) with zero effect as making the result potentially subject to publication bias and therefore unreliable. We also attempted to mitigate the potential for publication bias by searching the website <a href="http://www.clinicaltrials.gov." target="_blank">http://www.clinicaltrials.gov.</a> </p> </section> <section id="CD006883-sec-0052"> <h4 class="title">Data synthesis</h4> <p>We employed a fixed‐effect model (<a href="./references#CD006883-bbs2-0038" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Chichester: John Wiley &amp; Sons, 2011. ">Deeks 2011</a>), using Review Manager 5.3, to combine outcomes data at comparable time points. </p> </section> <section id="CD006883-sec-0053"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had planned to separately analyse studies that evaluated different types of scoliosis, antifibrinolytic drugs and control groups. However, we performed only the subgroup analysis evaluating the type of antifibrinolytic drug. We could not perform the subgroup analysis examining type of scoliosis because only two of the four studies that evaluated secondary and idiopathic scoliosis provided outcome data by type of scoliosis. Similarly, we could not perform the subgroup analysis by type of control group (e.g. use of desmopressin or a different antifibrinolytic instead of placebo) because all but one study employed placebo as control. </p> </section> <section id="CD006883-sec-0054"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis using a random‐effects model instead of our original fixed‐effect model. </p> <section id="CD006883-sec-0055"> <h5 class="title">Summary of findings</h5> <p>We included 'Summary of findings' tables as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, Chapter 4.6.6 (<a href="./references#CD006883-bbs2-0049" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. www.cochrane‐handbook.org. Vol. 5.1.0, The Cochrane Collaboration, 2011. ">Higgins 2011</a>). These 'Summary of findings' tables (<a href="./full#CD006883-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD006883-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD006883-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD006883-tbl-0004">summary of findings Table 4</a>) include outcomes of total blood loss, number of participants receiving blood transfusion and numbers of participants requiring blood transfusion with allogeneic blood and total blood transfused. We assessed the overall quality of the evidence for each outcome using the GRADE system (<a href="./references#CD006883-bbs2-0045" title="BrozekJ , OxmanA , SchünemannH . GRADEpro Guideline Development Tool [Software]. McMaster University (developed by Evidence Prime, Inc.), 2015. ">GRADEpro GDT 2015</a>) and presented our findings in the 'Summary of findings' tables. In particular, we included key information concerning the quality of evidence, the magnitude of effect of the interventions examined and the sum of available data on the main outcomes. </p> <p>The GRADE system uses the following criteria in assigning grade of evidence.</p> <p> <ul id="CD006883-list-0005"> <li> <p>High = Further research is very unlikely to change our confidence in the estimate of effect. </p> </li> <li> <p>Moderate = Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </li> <li> <p>Low = Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </li> <li> <p>Very low = Any estimate of effect is very uncertain.</p> </li> </ul> </p> <p>We decreased GRADE in cases of:</p> <p> <ul id="CD006883-list-0006"> <li> <p>serious (‐1) or very serious (‐2) limitations to study quality;</p> </li> <li> <p>important inconsistency (‐1);</p> </li> <li> <p>some (‐1) or major (‐2) uncertainty about directness;</p> </li> <li> <p>imprecise or sparse data (‐1); and</p> </li> <li> <p>high probability of reporting bias (‐1).</p> </li> </ul> </p> <p>We increased GRADE if we found:</p> <p> <ul id="CD006883-list-0007"> <li> <p>strong evidence of association (significant relative risk &gt; 2 or &lt; 0.5) based on consistent evidence from two or more observational studies, with no plausible confounders (+1); </p> </li> <li> <p>very strong evidence of association (significant relative risk &gt; 5 or &lt; 0.2) based on direct evidence with no major threats to validity (+2); </p> </li> <li> <p>evidence of a dose‐response gradient (+1); or</p> </li> <li> <p>all plausible confounders reducing the effect (+1).</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006883-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006883-sec-0056"></div> <section id="CD006883-sec-0057"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD006883-sec-0111" title="">Characteristics of included studies</a> and <a href="./references#CD006883-sec-0112" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD006883-sec-0058"> <h4 class="title">Results of the search</h4> <p>Our 2007 literature search yielded 506 citations (<a href="./references#CD006883-bbs2-0083" title="TzortzopoulouA , CepedaMS , SchumannR , CarrDB . Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006883.pub2] ">Tzortzopoulou 2008b</a>). We found no studies in the planning or recruitment phase. After screening, we identified 13 potentially relevant studies. The literature search covering 2007 to 2015 yielded an additional 130 citations (28 from CENTRAL; 26 from MEDLINE; 43 from EMBASE; five from DARE; and 28 from LILACS), of which we selected 12 for possible inclusion (<a href="#CD006883-fig-0001">Figure 1</a>). Additionally, we found one ongoing study on <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> (<a href="./references#CD006883-bbs2-0026" title="The Efficacy of Intravenous Tranexamic Acid in Decreasing Blood Loss in Pediatric Idiopathic Scoliosis Surgery?. Ongoing studyJanuary 2013. ">NCT01813058</a>). </p> <div class="figure" id="CD006883-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006883-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD006883-sec-0059"> <h4 class="title">Included studies</h4> <p>We included in the updated review nine studies (six from the original review (<a href="./references#CD006883-bbs2-0083" title="TzortzopoulouA , CepedaMS , SchumannR , CarrDB . Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD006883.pub2] ">Tzortzopoulou 2008b</a>) and three from the update) enrolling a total of 455 participants (see <a href="./references#CD006883-sec-0111" title="">Characteristics of included studies</a> table). Three included studies were presented in abstract form only, with no subsequent full publication (<a href="./references#CD006883-bbs2-0001" title="ColeJ , MurrayD , LenkeLG . Use of Amicar vs aprotinin during pediatric deformity surgery. Can they help decrease blood loss?. Scoliosis Research Society Annual Meeting. Seattle, September 18‐21, 2002. ">Cole 2002</a>; <a href="./references#CD006883-bbs2-0003" title="EnX . Efficacy of reptilase, tranexamic acid or both combined in adolescent idiopathic scoliosis surgery: a prospective, randomized, double‐blind, placebo‐controlled study. Spine Journal2014;14:35S. ">En 2014</a>; <a href="./references#CD006883-bbs2-0007" title="MoguilevitchM , SarwahiV . Methods to reduce blood loss in pediatric scoliosis surgery. European Journal of Anaesthesiology2011;28:88‐9. ">Moguilevitch 2011</a>). One of the studies was conducted in China (<a href="./references#CD006883-bbs2-0003" title="EnX . Efficacy of reptilase, tranexamic acid or both combined in adolescent idiopathic scoliosis surgery: a prospective, randomized, double‐blind, placebo‐controlled study. Spine Journal2014;14:35S. ">En 2014</a>), two in Canada (<a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>; <a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>) and the remainder in the USA (<a href="./references#CD006883-bbs2-0001" title="ColeJ , MurrayD , LenkeLG . Use of Amicar vs aprotinin during pediatric deformity surgery. Can they help decrease blood loss?. Scoliosis Research Society Annual Meeting. Seattle, September 18‐21, 2002. ">Cole 2002</a>; <a href="./references#CD006883-bbs2-0002" title="ColeJW , MurrayDJ , SniderRJ , BassettGS , BridwellKH , LenkeLG . Aprotinin reduces blood loss during spinal surgery in children. Spine2003;28(21):2482‐5. [MEDLINE: 14595168] ">Cole 2003</a>; <a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>; <a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>; <a href="./references#CD006883-bbs2-0007" title="MoguilevitchM , SarwahiV . Methods to reduce blood loss in pediatric scoliosis surgery. European Journal of Anaesthesiology2011;28:88‐9. ">Moguilevitch 2011</a>; <a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>). One study received no external funding (<a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>). Two studies received grants from organizations of healthcare professionals (<a href="./references#CD006883-bbs2-0002" title="ColeJW , MurrayDJ , SniderRJ , BassettGS , BridwellKH , LenkeLG . Aprotinin reduces blood loss during spinal surgery in children. Spine2003;28(21):2482‐5. [MEDLINE: 14595168] ">Cole 2003</a>; <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>), and one was sponsored by a pharmaceutical company (<a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>). The remaining studies did not report sources of funding. </p> <p>Total enrolment in each study ranged from 36 participants (<a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>) to 80 participants (<a href="./references#CD006883-bbs2-0003" title="EnX . Efficacy of reptilase, tranexamic acid or both combined in adolescent idiopathic scoliosis surgery: a prospective, randomized, double‐blind, placebo‐controlled study. Spine Journal2014;14:35S. ">En 2014</a>). The authors of one study (<a href="./references#CD006883-bbs2-0003" title="EnX . Efficacy of reptilase, tranexamic acid or both combined in adolescent idiopathic scoliosis surgery: a prospective, randomized, double‐blind, placebo‐controlled study. Spine Journal2014;14:35S. ">En 2014</a>) did not describe how many of the 80 participants were assigned to each intervention group (this study included a total of four intervention groups). Of 375 participants enrolled in the other studies, 159 were allocated to placebo and 216 to antifibrinolytic drugs. Among participants assigned to receive antifibrinolytics, 111 received aminocaproic acid, 36 aprotinin and 69 tranexamic acid (participants in <a href="./references#CD006883-bbs2-0003" title="EnX . Efficacy of reptilase, tranexamic acid or both combined in adolescent idiopathic scoliosis surgery: a prospective, randomized, double‐blind, placebo‐controlled study. Spine Journal2014;14:35S. ">En 2014</a> also received tranexamic acid, but as noted, the number assigned was not stated). Two of the studies evaluated aprotinin (<a href="./references#CD006883-bbs2-0002" title="ColeJW , MurrayDJ , SniderRJ , BassettGS , BridwellKH , LenkeLG . Aprotinin reduces blood loss during spinal surgery in children. Spine2003;28(21):2482‐5. [MEDLINE: 14595168] ">Cole 2003</a>; <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>), four tranexamic acid (<a href="./references#CD006883-bbs2-0003" title="EnX . Efficacy of reptilase, tranexamic acid or both combined in adolescent idiopathic scoliosis surgery: a prospective, randomized, double‐blind, placebo‐controlled study. Spine Journal2014;14:35S. ">En 2014</a>; <a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>; <a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>; <a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>) and four aminocaproic acid (<a href="./references#CD006883-bbs2-0001" title="ColeJ , MurrayD , LenkeLG . Use of Amicar vs aprotinin during pediatric deformity surgery. Can they help decrease blood loss?. Scoliosis Research Society Annual Meeting. Seattle, September 18‐21, 2002. ">Cole 2002</a>; <a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>; <a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>; <a href="./references#CD006883-bbs2-0007" title="MoguilevitchM , SarwahiV . Methods to reduce blood loss in pediatric scoliosis surgery. European Journal of Anaesthesiology2011;28:88‐9. ">Moguilevitch 2011</a>). <a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a> compared aminocaproic acid with tranexamic acid. The remaining studies administered placebo in the control group. Studies that evaluated aprotinin (<a href="./references#CD006883-bbs2-0002" title="ColeJW , MurrayDJ , SniderRJ , BassettGS , BridwellKH , LenkeLG . Aprotinin reduces blood loss during spinal surgery in children. Spine2003;28(21):2482‐5. [MEDLINE: 14595168] ">Cole 2003</a>; <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>) employed high dose regimens. Similarly, studies that administered aminocaproic acid and reported such information used high dose regimens (<a href="./references#CD006883-bbs2-0001" title="ColeJ , MurrayD , LenkeLG . Use of Amicar vs aprotinin during pediatric deformity surgery. Can they help decrease blood loss?. Scoliosis Research Society Annual Meeting. Seattle, September 18‐21, 2002. ">Cole 2002</a>; <a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>; <a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>). <a href="./references#CD006883-bbs2-0007" title="MoguilevitchM , SarwahiV . Methods to reduce blood loss in pediatric scoliosis surgery. European Journal of Anaesthesiology2011;28:88‐9. ">Moguilevitch 2011</a> did not describe the dosing regimen. Among studies that evaluated tranexamic acid, two evaluated high dose regimens (<a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>; <a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>) and one a low dose regimen (<a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>), and one did not describe the dose administered (<a href="./references#CD006883-bbs2-0003" title="EnX . Efficacy of reptilase, tranexamic acid or both combined in adolescent idiopathic scoliosis surgery: a prospective, randomized, double‐blind, placebo‐controlled study. Spine Journal2014;14:35S. ">En 2014</a>). Details on doses are found in the <a href="./references#CD006883-sec-0111" title="">Characteristics of included studies</a> table. </p> <p>Five studies evaluated idiopathic scoliosis (<a href="./references#CD006883-bbs2-0001" title="ColeJ , MurrayD , LenkeLG . Use of Amicar vs aprotinin during pediatric deformity surgery. Can they help decrease blood loss?. Scoliosis Research Society Annual Meeting. Seattle, September 18‐21, 2002. ">Cole 2002</a>; <a href="./references#CD006883-bbs2-0003" title="EnX . Efficacy of reptilase, tranexamic acid or both combined in adolescent idiopathic scoliosis surgery: a prospective, randomized, double‐blind, placebo‐controlled study. Spine Journal2014;14:35S. ">En 2014</a>; <a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>; <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>; <a href="./references#CD006883-bbs2-0007" title="MoguilevitchM , SarwahiV . Methods to reduce blood loss in pediatric scoliosis surgery. European Journal of Anaesthesiology2011;28:88‐9. ">Moguilevitch 2011</a>), and four evaluated both idiopathic and secondary scoliosis (<a href="./references#CD006883-bbs2-0002" title="ColeJW , MurrayDJ , SniderRJ , BassettGS , BridwellKH , LenkeLG . Aprotinin reduces blood loss during spinal surgery in children. Spine2003;28(21):2482‐5. [MEDLINE: 14595168] ">Cole 2003</a>; <a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>; <a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>; <a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>). </p> <p>Four studies provided information on blood loss and blood transfusion during the intraoperative period only (<a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>;<a href="./references#CD006883-bbs2-0007" title="MoguilevitchM , SarwahiV . Methods to reduce blood loss in pediatric scoliosis surgery. European Journal of Anaesthesiology2011;28:88‐9. ">Moguilevitch 2011</a>; <a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>;<a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>), one reported a combined estimate of blood loss and blood transfusion during intraoperative and postoperative periods combined (<a href="./references#CD006883-bbs2-0002" title="ColeJW , MurrayDJ , SniderRJ , BassettGS , BridwellKH , LenkeLG . Aprotinin reduces blood loss during spinal surgery in children. Spine2003;28(21):2482‐5. [MEDLINE: 14595168] ">Cole 2003</a>) and one provided information on these periods separately (<a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>). <a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a> performed two separate analyses, that is, total blood loss during the intraoperative period only and total blood loss during intraoperative and postoperative periods combined (to include participants who had postoperative suction drains). In one study, it was unclear which periods were assessed (<a href="./references#CD006883-bbs2-0003" title="EnX . Efficacy of reptilase, tranexamic acid or both combined in adolescent idiopathic scoliosis surgery: a prospective, randomized, double‐blind, placebo‐controlled study. Spine Journal2014;14:35S. ">En 2014</a>). </p> <p>Of the nine studies, five reported the period of follow‐up (<a href="./references#CD006883-bbs2-0002" title="ColeJW , MurrayDJ , SniderRJ , BassettGS , BridwellKH , LenkeLG . Aprotinin reduces blood loss during spinal surgery in children. Spine2003;28(21):2482‐5. [MEDLINE: 14595168] ">Cole 2003</a>; <a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>; <a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>; <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>; <a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>). Follow‐up ranged from one to 10 days after surgery or was provided over the participant's length of stay (<a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>). </p> <p>Of the nine included studies, six reported a transfusion threshold. Transfusion thresholds were similar among studies. Participants were transfused when haemoglobin (Hgb) levels were below 7 g/dL and/or haematocrit (Htc) levels were below 21%, or when participants presented with clinical symptoms of hypovolaemia (<a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>;<a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>; <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>; <a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>). Two studies applied higher Htc thresholds (27%) (<a href="./references#CD006883-bbs2-0002" title="ColeJW , MurrayDJ , SniderRJ , BassettGS , BridwellKH , LenkeLG . Aprotinin reduces blood loss during spinal surgery in children. Spine2003;28(21):2482‐5. [MEDLINE: 14595168] ">Cole 2003</a>; <a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>). </p> </section> <section id="CD006883-sec-0060"> <h4 class="title">Excluded studies</h4> <p>Sixteen studies did not meet inclusion criteria (see <a href="./references#CD006883-sec-0112" title="">Characteristics of excluded studies</a> table). Reasons for exclusion included lack of randomization (<a href="./references#CD006883-bbs2-0013" title="Florentino‐PinedaI , BlakemoreLC , ThompsonGH , Poe‐KochertC , AdlerP , TripiP . The effect of epsilon‐aminocaproic acid on perioperative blood loss in patients with idiopathic scoliosis undergoing posterior spinal fusion: a preliminary prospective study. Spine2001;26(10):1147‐51. [MEDLINE: 11413428] ">Florentino 2001</a>; <a href="./references#CD006883-bbs2-0019" title="ParkHG , YooBH , LeeSS , YonJH , HongKH . The effect of low dose aprotinin in patients with adolescent idiopathic scoliosis undergoing posterior spinal fusion. Anesthesia and Pain Medicine2008;3:178‐82. [Abstract Number: A1059] ">Park 2008</a>; <a href="./references#CD006883-bbs2-0020" title="ShapiroF , ZurakowskiD , SethnaN . Tranexamic acid diminishes intraoperative blood loss and transfusion in spinal fusions for Duchenne muscular dystrophy scoliosis. Spine2007;32:2278‐83. ">Shapiro 2007</a>; <a href="./references#CD006883-bbs2-0022" title="ThompsonGH , Florentino‐PinedaI , ArmstrongDG , Poe‐KochertC . Fibrinogen levels following Amicar in surgery for idiopathic scoliosis. Spine2007;32:368‐72. [MEDLINE: 17268270] ">Thompson 2007</a>; <a href="./references#CD006883-bbs2-0023" title="VermaRR , WilliamsonJB , DashtiH , PatelD , OxborrowNJ . Homologous blood transfusion is not required in surgery for adolescent idiopathic scoliosis. Journal of Bone and Joint Surgery. British volume2006;88(9):1187‐91. [MEDLINE: 16943470] ">Verma 2006</a>); no report of participant age (<a href="./references#CD006883-bbs2-0010" title="BarrenaOMA , EscobarIC , CallejaDM , MarreroEF , RojasARG . Use of epsilon‐aminocaproic acid to reduce bleeding in scoliosis surgery: clinical trial [Uso del ácido épsilon‐aminocaproico para disminuir el sangrado en la cirugía de escoliosis: ensayo clínico]. Revista Argentina de Anestesiología2002;60:292‐8. ">Barrena 2002</a>); evaluation of only adults or no separate evaluations of children and adults (<a href="./references#CD006883-bbs2-0011" title="BarrenaOMA , CallejaDM , EscobarIC , MarreroEF . Use of epsilon amino caproic acid for surgical correction of scoliosis in patients with Marfan syndrome. Revista Mexicana de Anestesiologia2003;26(1):17‐20. ">Barrena 2003</a>; <a href="./references#CD006883-bbs2-0012" title="BoenigkK , VermaK , HoelscherC , HunckeKT , LonnerB , ErricoT . The efficacy of antifibrinolytics at reducing blood loss in major spine surgery: a prospective randomized comparison of tranexamic acid, aminocaproic acid and placebo. European Journal of Anaesthesiology2011;28:90. ">Boenigk 2011</a>; <a href="./references#CD006883-bbs2-0015" title="HoelscherC , VermaK , ErricoT , DryerJ , HunckeT , BoenigkK , et al. Are antifibrinolytics effective at reducing peri‐operative blood loss in adolescent idiopathic scoliosis?. Spine Journal2011;11:67S. ">Hoelscher 2011</a>; <a href="./references#CD006883-bbs2-0016" title="KarapurkarA , KudalkarA , NailL . Aprotinin to reduce perioperative blood loss in scoliosis surgery. Indian Journal of Anaesthesiology2002;46(5):378‐80. ">Karapurkar 2002</a>; <a href="./references#CD006883-bbs2-0017" title="LentschenerC , CottinP , BouazizH , MercierFJ , WolfM , AljabiY , et al. Reduction of blood loss and transfusion requirement by aprotinin in posterior lumbar spine fusion. Anesthesia and Analgesia1999;89(3):590‐7. [MEDLINE: 10475286] ">Lentschener 1999</a>; <a href="./references#CD006883-bbs2-0024" title="VermaK , ErricoT , DiefenbachC , HoelscherC , PetersA , DryerJ , et al. The relative efficacy of antifibrinolytics in adolescent idiopathic scoliosis: a prospective randomized trial. Journal of Bone and Joint Surgery. American volume2014;96:e80. VermaK , ErricoTJ , VazKM , LonnerBS . A prospective, randomized, double blinded single‐site control study comparing blood loss prevention of tranexamic acid (TXA) to epsilon aminocaproic acid (EACA) for corrective spinal surgery. BMC Surgery2010;10(13):Epub. [DOI: 10.1186/1471‐2482‐10‐13] ">Verma 2014</a>; <a href="./references#CD006883-bbs2-0025" title="XuC , WuA , YueY . Which is more effective in adolescent idiopathic scoliosis surgery: batroxobin, tranexamic acid or a combination?. Archives of Orthopaedic and Trauma Surgery2012;132:25‐31. ">Xu 2012</a>); duplicate studies (<a href="./references#CD006883-bbs2-0014" title="HaynesRJ . Aprotinin reduced blood loss in long‐segment posterior spinal fusion. Journal of Bone and Joint Surgery. American volume2004;86:1102. ">Haynes 2004</a>; <a href="./references#CD006883-bbs2-0021" title="ThompsonGH , Florentino‐PinedaI , Poe‐KochertC . The role of Amicar in decreasing perioperative blood loss in idiopathic scoliosis. Spine2005;30:S94‐9. ">Thompson 2005</a>); and evaluation of mixed surgeries with no separate evaluation of data from scoliosis surgery (<a href="./references#CD006883-bbs2-0018" title="LlauJV , HoyasL , HiguerasJ , EzpeletaJ , García‐PolitJ . Aprotinin reduces intraoperative bleeding during spinal arthrodesis interventions [La aprotinina reduce el sangrado intraoperatorio en las intervenciones de artrodesis raquideas]. Revista Española de Anestesiología y Reanimación1996;43:118. ">Llau 1996</a>). </p> <section id="CD006883-sec-0061"> <h5 class="title">Ongoing studies</h5> <p>We found one ongoing study on clinicaltrials.gov (<a href="./references#CD006883-bbs2-0026" title="The Efficacy of Intravenous Tranexamic Acid in Decreasing Blood Loss in Pediatric Idiopathic Scoliosis Surgery?. Ongoing studyJanuary 2013. ">NCT01813058</a>; see <a href="./references#CD006883-sec-0113" title="">Characteristics of ongoing studies</a>). </p> </section> <section id="CD006883-sec-0062"> <h5 class="title">Studies awaiting classification</h5> <p>We found no studies awaiting classification.</p> </section> </section> </section> <section id="CD006883-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>We have summarised our findings in <a href="#CD006883-fig-0002">Figure 2</a> and <a href="#CD006883-fig-0003">Figure 3</a>. Most "unclear" assessments resulted from the fact that three of the studies were published in abstract form only (<a href="./references#CD006883-bbs2-0001" title="ColeJ , MurrayD , LenkeLG . Use of Amicar vs aprotinin during pediatric deformity surgery. Can they help decrease blood loss?. Scoliosis Research Society Annual Meeting. Seattle, September 18‐21, 2002. ">Cole 2002</a>; <a href="./references#CD006883-bbs2-0003" title="EnX . Efficacy of reptilase, tranexamic acid or both combined in adolescent idiopathic scoliosis surgery: a prospective, randomized, double‐blind, placebo‐controlled study. Spine Journal2014;14:35S. ">En 2014</a>; <a href="./references#CD006883-bbs2-0007" title="MoguilevitchM , SarwahiV . Methods to reduce blood loss in pediatric scoliosis surgery. European Journal of Anaesthesiology2011;28:88‐9. ">Moguilevitch 2011</a>). </p> <div class="figure" id="CD006883-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006883-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD006883-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006883-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD006883-sec-0064"> <h4 class="title">Allocation</h4> <p>Six studies adequately described the method of randomization (<a href="./references#CD006883-bbs2-0002" title="ColeJW , MurrayDJ , SniderRJ , BassettGS , BridwellKH , LenkeLG . Aprotinin reduces blood loss during spinal surgery in children. Spine2003;28(21):2482‐5. [MEDLINE: 14595168] ">Cole 2003;</a><a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>; <a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>; <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>; <a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>; <a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>). The remaining studies did not describe the method of randomization used. We assessed fewer studies as providing clear documentation of adequate allocation concealment (<a href="./references#CD006883-bbs2-0002" title="ColeJW , MurrayDJ , SniderRJ , BassettGS , BridwellKH , LenkeLG . Aprotinin reduces blood loss during spinal surgery in children. Spine2003;28(21):2482‐5. [MEDLINE: 14595168] ">Cole 2003</a>; <a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>; <a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>) and noted that six studies did not describe the method of allocation concealment used (<a href="./references#CD006883-bbs2-0001" title="ColeJ , MurrayD , LenkeLG . Use of Amicar vs aprotinin during pediatric deformity surgery. Can they help decrease blood loss?. Scoliosis Research Society Annual Meeting. Seattle, September 18‐21, 2002. ">Cole 2002;</a><a href="./references#CD006883-bbs2-0003" title="EnX . Efficacy of reptilase, tranexamic acid or both combined in adolescent idiopathic scoliosis surgery: a prospective, randomized, double‐blind, placebo‐controlled study. Spine Journal2014;14:35S. ">En 2014</a>; <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>; <a href="./references#CD006883-bbs2-0007" title="MoguilevitchM , SarwahiV . Methods to reduce blood loss in pediatric scoliosis surgery. European Journal of Anaesthesiology2011;28:88‐9. ">Moguilevitch 2011</a>; <a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>; <a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>). </p> </section> <section id="CD006883-sec-0065"> <h4 class="title">Blinding</h4> <p>Three studies employed adequate methods to ensure blinding (<a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>; <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>; <a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>). Interventions were prepared by a party not directly involved in the study, and study authors explicitly stated that the interventions appeared identical. Of the six studies in which the adequacy of blinding was unclear, three (<a href="./references#CD006883-bbs2-0002" title="ColeJW , MurrayDJ , SniderRJ , BassettGS , BridwellKH , LenkeLG . Aprotinin reduces blood loss during spinal surgery in children. Spine2003;28(21):2482‐5. [MEDLINE: 14595168] ">Cole 2003</a>; <a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>; <a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>) provided some description of their method (e.g. a third party prepared the interventions) but did not provide enough information that we could be certain (e.g. no mention of whether treatments appeared identical) and three papers did not describe the blinding method in any way (<a href="./references#CD006883-bbs2-0001" title="ColeJ , MurrayD , LenkeLG . Use of Amicar vs aprotinin during pediatric deformity surgery. Can they help decrease blood loss?. Scoliosis Research Society Annual Meeting. Seattle, September 18‐21, 2002. ">Cole 2002</a>; <a href="./references#CD006883-bbs2-0003" title="EnX . Efficacy of reptilase, tranexamic acid or both combined in adolescent idiopathic scoliosis surgery: a prospective, randomized, double‐blind, placebo‐controlled study. Spine Journal2014;14:35S. ">En 2014</a>; <a href="./references#CD006883-bbs2-0007" title="MoguilevitchM , SarwahiV . Methods to reduce blood loss in pediatric scoliosis surgery. European Journal of Anaesthesiology2011;28:88‐9. ">Moguilevitch 2011</a>). </p> </section> <section id="CD006883-sec-0066"> <h4 class="title">Incomplete outcome data</h4> <p>Generally, owing to the acute nature of the studies, numbers of participants withdrawn were low and missing data minimal. We assessed seven studies as having low risk of bias (<a href="./references#CD006883-bbs2-0001" title="ColeJ , MurrayD , LenkeLG . Use of Amicar vs aprotinin during pediatric deformity surgery. Can they help decrease blood loss?. Scoliosis Research Society Annual Meeting. Seattle, September 18‐21, 2002. ">Cole 2002</a>; <a href="./references#CD006883-bbs2-0002" title="ColeJW , MurrayDJ , SniderRJ , BassettGS , BridwellKH , LenkeLG . Aprotinin reduces blood loss during spinal surgery in children. Spine2003;28(21):2482‐5. [MEDLINE: 14595168] ">Cole 2003</a>; <a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>; <a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>; <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>; <a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>; <a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>), as it appeared that all participants completed the trials and contributed data to the efficacy outcomes. We assigned two as having unclear risk, as study authors did not describe how many participants completed the respective trials (<a href="./references#CD006883-bbs2-0003" title="EnX . Efficacy of reptilase, tranexamic acid or both combined in adolescent idiopathic scoliosis surgery: a prospective, randomized, double‐blind, placebo‐controlled study. Spine Journal2014;14:35S. ">En 2014</a>; <a href="./references#CD006883-bbs2-0007" title="MoguilevitchM , SarwahiV . Methods to reduce blood loss in pediatric scoliosis surgery. European Journal of Anaesthesiology2011;28:88‐9. ">Moguilevitch 2011</a>). </p> </section> <section id="CD006883-sec-0067"> <h4 class="title">Selective reporting</h4> <p>We assessed only one study as having low risk of selective reporting bias (<a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>). This study fully reported results of all outcomes described in the Methods section. Although we cannot rule out the possibility that data were eliminated from both the Methods and Results sections (i.e. data that were part of the original study were not reported), the main outcomes reported were those expected in this type of study. Two studies were assessed as having high risk of bias (<a href="./references#CD006883-bbs2-0001" title="ColeJ , MurrayD , LenkeLG . Use of Amicar vs aprotinin during pediatric deformity surgery. Can they help decrease blood loss?. Scoliosis Research Society Annual Meeting. Seattle, September 18‐21, 2002. ">Cole 2002</a>; <a href="./references#CD006883-bbs2-0003" title="EnX . Efficacy of reptilase, tranexamic acid or both combined in adolescent idiopathic scoliosis surgery: a prospective, randomized, double‐blind, placebo‐controlled study. Spine Journal2014;14:35S. ">En 2014</a>), as they presented data without measures of variability and made no mention of AE assessment. We assessed the remaining studies as having unclear risk, mostly because they did not clearly describe outcomes in their Methods section and/or because their assessments of AEs were inadequate or were incompletely described (<a href="./references#CD006883-bbs2-0002" title="ColeJW , MurrayDJ , SniderRJ , BassettGS , BridwellKH , LenkeLG . Aprotinin reduces blood loss during spinal surgery in children. Spine2003;28(21):2482‐5. [MEDLINE: 14595168] ">Cole 2003</a>; <a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>; <a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>; <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>; <a href="./references#CD006883-bbs2-0007" title="MoguilevitchM , SarwahiV . Methods to reduce blood loss in pediatric scoliosis surgery. European Journal of Anaesthesiology2011;28:88‐9. ">Moguilevitch 2011</a>; <a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>). </p> </section> <section id="CD006883-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <p>We assessed all nine studies as having high risk of bias because of study size (i.e. number of participants enrolled). No study enrolled more than 50 participants in any arm. The maximum confirmed number of participants in active and control groups was 40 and 32, respectively, in <a href="./references#CD006883-bbs2-0007" title="MoguilevitchM , SarwahiV . Methods to reduce blood loss in pediatric scoliosis surgery. European Journal of Anaesthesiology2011;28:88‐9. ">Moguilevitch 2011</a>. </p> </section> </section> <section id="CD006883-sec-0069"> <h3 class="title" id="CD006883-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD006883-tbl-0001"><b>Summary of findings for the main comparison</b> Mean total blood loss (mL)</a>; <a href="./full#CD006883-tbl-0002"><b>Summary of findings 2</b> Number of participants receiving blood transfusion</a>; <a href="./full#CD006883-tbl-0003"><b>Summary of findings 3</b> Number of participants receiving transfusion with allogeneic blood</a>; <a href="./full#CD006883-tbl-0004"><b>Summary of findings 4</b> Mean total volume of blood transfused (mL)</a> </p> <p>Two studies provided no data that could be used in efficacy or safety analyses. <a href="./references#CD006883-bbs2-0001" title="ColeJ , MurrayD , LenkeLG . Use of Amicar vs aprotinin during pediatric deformity surgery. Can they help decrease blood loss?. Scoliosis Research Society Annual Meeting. Seattle, September 18‐21, 2002. ">Cole 2002</a> was published as an abstract and did not provide measures of variability. <a href="./references#CD006883-bbs2-0003" title="EnX . Efficacy of reptilase, tranexamic acid or both combined in adolescent idiopathic scoliosis surgery: a prospective, randomized, double‐blind, placebo‐controlled study. Spine Journal2014;14:35S. ">En 2014</a> was also published as an abstract and presented data as percentages without describing how many participants were assigned to each group. </p> <section id="CD006883-sec-0070"> <h4 class="title">Primary outcome</h4> <section id="CD006883-sec-0071"> <h5 class="title">Mean total blood loss</h5> <p>None of the included studies from the updated review provided data for the outcome of mean total blood loss when comparing antifibrinolytics versus placebo (<a href="./references#CD006883-fig-0007" title="">Analysis 1.1</a>; <a href="#CD006883-fig-0004">Figure 4</a>; <a href="./full#CD006883-tbl-0001">summary of findings Table for the main comparison</a>). Therefore, as in our previous review, our meta‐analysis included 100 participants receiving antifibrinolytic drugs and 107 receiving placebo. We merged intraoperative and postoperative periods of evaluation and found that the results were homogeneous (I<sup>2</sup> = 0%). Antifibrinolytic drugs decreased mean perioperative blood loss by 427 mL (95% confidence interval (CI) 251 to 603 mL), for a reduction of over 20% versus placebo. Although we presented data separately for each agent (aminocaproic acid, aprotinin and tranexamic acid), numbers of participants for individual drugs were insufficient for a meaningful subgroup analysis. We rated the quality of evidence for our primary outcome as low, on the basis of unclear risk of bias for several domains in most studies and the small total number of participants (imprecision). </p> <div class="figure" id="CD006883-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Mean total blood loss (mL), outcome: 1.1 Antifibrinolytics versus placebo." data-id="CD006883-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Mean total blood loss (mL), outcome: 1.1 Antifibrinolytics versus placebo. </p> </div> </div> </div> <p>One study from our updated search (<a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>) compared aminocaproic acid with tranexamic acid and found a non‐statistically significant increase in mean calculated blood loss among those receiving aminocaproic acid (mean difference (MD) 463 mL, 95% CI ‐155 to 1081 mL; 44 participants; <a href="./references#CD006883-fig-0008" title="">Analysis 1.2</a>). Investigators assessed calculated blood loss by attempting to collect all blood loss into the cell saver system and weighing all sponges. They calculated blood loss by subtracting the volume of heparinised saline from the total volume in the cell saver system and the average dry sponge weight from blood‐soaked sponges. They then combined these values to determine total blood loss. For the two participants in whom a postoperative suction drain was used (both received aminocaproic acid), they added this volume to the calculated blood loss in a separate analysis. This analysis increased the calculated mean blood loss in the aminocaproic acid group to 1422 mL. We chose to present only intraoperative blood loss data for this comparison, as postoperative blood loss could not be calculated in those without a suction drain. Results from standard estimated blood loss (estimates made in the operating room by looking at the wound, drapes, drain canisters, sponges, etc.) demonstrated similar differences between agents, with lower estimates of mean blood loss in each group. </p> </section> </section> <section id="CD006883-sec-0072"> <h4 class="title">Secondary outcomes</h4> <section id="CD006883-sec-0073"> <h5 class="title">Number of participants transfused</h5> <p>Four studies provided data on the number of children requiring transfusion (<a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>; <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>; <a href="./references#CD006883-bbs2-0007" title="MoguilevitchM , SarwahiV . Methods to reduce blood loss in pediatric scoliosis surgery. European Journal of Anaesthesiology2011;28:88‐9. ">Moguilevitch 2011</a>; <a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>). Of 97 (36%) participants receiving antifibrinolytic drugs, 35 needed transfusion versus 59 of 98 (60%) receiving placebo (risk ratio (RR) 0.65, 95% CI 0.50 to 0.85; <a href="./references#CD006883-fig-0009" title="">Analysis 2.1</a>; <a href="#CD006883-fig-0005">Figure 5</a>; <a href="./full#CD006883-tbl-0002">summary of findings Table 2</a>). This translates to an NNTp of 5 (95% CI 4 to 13) (i.e. five participants would need to be treated with an antifibrinolytic to prevent the need for transfusion that would have occurred had they received placebo). We judged these results as having high susceptibility to publication bias, in that fewer than 400 (calculation = 211) additional participants would be needed in studies with zero effect to increase the NNTp for number of participants transfused to 10 or greater. </p> <div class="figure" id="CD006883-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Number of participants receiving blood transfusion, outcome: 2.1 Antifibrinolytics versus placebo." data-id="CD006883-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Number of participants receiving blood transfusion, outcome: 2.1 Antifibrinolytics versus placebo. </p> </div> </div> </div> <p>We rated the quality of evidence for this outcome as very low on the basis of unclear risk of bias for several domains in most studies, the small total number of participants and susceptibility to publication bias in analyses that demonstrated a clinically significant effect or wide confidence intervals that included no effect (imprecision). </p> </section> <section id="CD006883-sec-0074"> <h5 class="title">Number of participants transfused with allogeneic blood</h5> <p>Only two studies, enrolling a total of 79 participants, specifically evaluated the number of participants requiring transfusion with allogeneic blood (<a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>; <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>). In one of these studies (<a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>), no participants in either group received transfusion with allogeneic blood. In <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>, none of the 15 participants receiving aprotinin required transfusion versus eight of 28 (29%) receiving placebo (RR 0.11, 95% CI 0.01 to 1.73; <a href="./references#CD006883-fig-0010" title="">Analysis 3.1</a>; <a href="./full#CD006883-tbl-0003">summary of findings Table 3</a>). The results are statistically significant when expressed as risk difference (RD ‐0.15, 95% CI ‐0.26 to ‐0.03), translating to an NNTp of 7 (95% CI 4 to 34) (i.e. seven participants would need to be treated with an antifibrinolytic to prevent the need for allogeneic transfusion that would have occurred had they received placebo). However, we judged these results as having high susceptibility to publication bias, in that fewer than 400 (calculation = 39) additional participants would be needed in studies with zero effect to increase the NNTp for the number of participants transfused to 10 or greater. We rated the quality of evidence for this outcome as very low on the basis of unclear risk of bias for several domains in most studies, inconsistency, small total number of participants and imprecision. </p> <p><a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a> compared allogeneic transfusion rates in participants receiving aminocaproic acid versus those receiving tranexamic acid (<a href="./references#CD006883-fig-0011" title="">Analysis 3.2</a>). Five of 23 participants (22%) in the aminocaproic acid group required blood transfusion versus three of 23 (13%) in the tranexamic acid group (RR 1.47, 95% CI 0.40 to 5.44), demonstrating a statistically insignificant trend towards reduced rates of infusion in the tranexamic acid group. </p> </section> <section id="CD006883-sec-0075"> <h5 class="title">Mean total volume of blood transfused</h5> <p>None of the included studies from the updated review provided additional data for the outcome of mean total volume of blood transfused when antifibrinolytics were compared with placebo (<a href="./references#CD006883-fig-0012" title="">Analysis 4.1</a>; <a href="#CD006883-fig-0006">Figure 6</a>; <a href="./full#CD006883-tbl-0004">summary of findings Table 4</a>). As with our estimates of blood loss, we merged intraoperative and postoperative periods of evaluation. Antifibrinolytic drugs decreased the mean amount of blood transfused by 327 mL (95% CI ‐186 to ‐469 mL). The results were homogeneous (I<sup>2</sup> = 0%). </p> <div class="figure" id="CD006883-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 Mean total blood transfused (mL), outcome: 4.1 Antifibrinolytics versus placebo." data-id="CD006883-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 Mean total blood transfused (mL), outcome: 4.1 Antifibrinolytics versus placebo. </p> </div> </div> </div> <p>We rated the quality of evidence for this outcome as low on the basis of unclear risk of bias for several domains in most studies and the small total number of participants. </p> </section> <section id="CD006883-sec-0076"> <h5 class="title">Mortality</h5> <p>Investigators reported no deaths in any study, in active or control groups, during surgery or during the one‐day to 10‐day follow‐up period after surgery (<a href="./references#CD006883-fig-0013" title="">Analysis 5.1</a>; <a href="./references#CD006883-fig-0014" title="">Analysis 5.2</a>). </p> </section> <section id="CD006883-sec-0077"> <h5 class="title">Adverse events</h5> <p>Data were insufficient to allow performance of meta‐analysis of safety data for any AE outcome (number of participants reporting any AE (<a href="./references#CD006883-fig-0015" title="">Analysis 6.1</a>; <a href="./references#CD006883-fig-0016" title="">Analysis 6.2</a>); number of participants experiencing a serious AE (<a href="./references#CD006883-fig-0017" title="">Analysis 7.1</a>; <a href="./references#CD006883-fig-0018" title="">Analysis 7.2</a>); number of participants withdrawing because of an AE (<a href="./references#CD006883-fig-0019" title="">Analysis 8.1</a>; <a href="./references#CD006883-fig-0020" title="">Analysis 8.2</a>); or number of participants experiencing specific AEs (i.e. renal insufficiency, hypersensitivity or thrombotic events) (<a href="./references#CD006883-fig-0021" title="">Analysis 9.1</a>; <a href="./references#CD006883-fig-0022" title="">Analysis 9.2</a>; <a href="./references#CD006883-fig-0023" title="">Analysis 10.1</a>; <a href="./references#CD006883-fig-0024" title="">Analysis 10.2</a>)). Studies did not report AEs or reported zero events. Only one study reported hypersensitivity rates, only to state that no participant in the antifibrinolytic group nor in the placebo group suffered such an event (<a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>). No studies adequately described their methods in assessing safety. The only AE of note occurred in <a href="./references#CD006883-bbs2-0002" title="ColeJW , MurrayDJ , SniderRJ , BassettGS , BridwellKH , LenkeLG . Aprotinin reduces blood loss during spinal surgery in children. Spine2003;28(21):2482‐5. [MEDLINE: 14595168] ">Cole 2003</a>, when three participants in the placebo group developed postoperative deep vein thrombosis. </p> </section> </section> <section id="CD006883-sec-0078"> <h4 class="title">Subgroup analyses and sensitivity analyses</h4> <p>We intended to perform subgroup and sensitivity analyses based on various study characteristics.</p> <section id="CD006883-sec-0079"> <h5 class="title">Subgroup analyses</h5> <p>As stated in the Methods section (<a href="#CD006883-sec-0053">Subgroup analysis and investigation of heterogeneity</a>), we had planned to separately analyse studies that evaluated different types of scoliosis, antifibrinolytic drugs and controls. However, we performed only the subgroup analysis examining types of antifibrinolytic drugs. The number of participants in the studies of individual agents was insufficient to enable meaningful analysis. </p> </section> <section id="CD006883-sec-0080"> <h5 class="title">Sensitivity analysis</h5> <p>We performed a sensitivity analysis using a random‐effects model instead of our original fixed‐effect model. Neither analysis of total blood loss nor analysis of total blood transfused was affected in any way (i.e. direction, magnitude nor statistical significance of effect). However, both of our analyses of participants receiving transfusion (overall or allogeneic) changed from statistically significant to non‐significant, reflecting heterogeneity between studies and small overall numbers. For participants receiving transfusion, the RR increased to 0.76 (95% CI 0.47 to 1.24), primarily owing to <a href="./references#CD006883-bbs2-0007" title="MoguilevitchM , SarwahiV . Methods to reduce blood loss in pediatric scoliosis surgery. European Journal of Anaesthesiology2011;28:88‐9. ">Moguilevitch 2011</a>, which reported a much smaller event rate in the antifibrinolytic group than was reported by the other studies. For participants requiring allogeneic transfusion, the best point estimate for risk difference was similar to that seen when a fixed‐effect model was employed (‐0.14 vs ‐0.15, respectively), but the 95% CI included no effect, most likely explained by the difference in event rates in placebo groups between studies. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006883-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006883-sec-0081"></div> <section id="CD006883-sec-0082"> <h3 class="title" id="CD006883-sec-0082">Summary of main results</h3> <p>In this update, review authors added three studies to the analysis of six studies from the original review. Analyses of mean total blood loss and mean amount of blood transfused remain unchanged from our original review, as no new studies contributed data to these comparisons. The addition of one study (<a href="./references#CD006883-bbs2-0007" title="MoguilevitchM , SarwahiV . Methods to reduce blood loss in pediatric scoliosis surgery. European Journal of Anaesthesiology2011;28:88‐9. ">Moguilevitch 2011</a>) to our analysis of number of participants receiving blood transfusion increased the overall superiority (risk reduction) of antifibrinolytics versus placebo and changed our estimate from non‐statistically significant to significant. However, the heterogeneity of the analysis also increased. The analysis of number of participants receiving allogeneic transfusion remained essentially unchanged, reflecting lack of available data for this outcome; we did, however, find a statistically significant absolute risk reduction between antifibrinolytics and placebo. Additionally, we made mean total blood loss our primary outcome for this updated review (as opposed to mortality and number of participants requiring transfusion ‐ primary outcomes in our original review). We made this change as we consider total blood loss to be the most clinically significant of our explored outcomes. Mortality is rare (it did not occur in any participants in our review) and may reflect factors other than blood loss, and the number of participants transfused is dependent on the threshold for transfusion, which may differ between studies (although thresholds were similar in the studies that reported them). Factors such as variation in physician practice may also have affected transfusion rates. We formally analyzed adverse event (AE) data. However, incomplete reporting (or inadequate assessment) and the rarity with which the chosen AEs occurred precluded meaningful analysis. </p> <section id="CD006883-sec-0083"> <h4 class="title">Efficacy</h4> <p>Limited evidence from our updated review suggests that aprotinin, tranexamic acid and aminocaproic acid administered to children undergoing scoliosis surgery decrease perioperative blood loss and the amount of blood transfused. Very limited data also demonstrate a reduction in the need for transfusion with autologous or allogeneic blood<i>.</i> </p> <p>The decrease in mean blood loss, on average 427 mL, associated with use of antifibrinolytic drugs is clinically important, especially for children, as their blood volume is less than that of adults. This quantity is also approximately the amount of blood in a unit of blood, which suggests that antifibrinolytic drugs could decrease the risk of any transfusion, or the risk of transfusion of an additional unit. Our findings are based mainly on studies that evaluated high‐dose drug regimens and, therefore, may not apply to use of lower doses. </p> <p>Although we considered the outcome of mean blood loss as the most clinically important, other clinicians consider the risk of requiring transfusion a more relevant outcome (<a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>). Reducing the need for allogeneic transfusions should, in turn, lower the risk of infection and other complications, such as transfusion reactions or circulatory overload. However, only two studies evaluated the proportion of participants transfused with allogeneic blood, and the confidence intervals around the best point estimate for this analysis are so wide that they are compatible with both no effect and a reduction in the risk of transfusion. Other products such as fresh frozen plasma, platelets or cryoprecipitate may be administered to restore coagulation factors when massive bleeding occurs. However, this systematic review focused on blood transfusion. As noted in <a href="#CD006883-sec-0034">Types of outcome measures</a>, transfusion triggers varied between studies, potentially confounding analysis of this outcome. We were able to obtain transfusion threshold data from four of the studies included in our transfusion analyses: In three of these studies, a haemoglobin level &lt; 7 g/dL routinely triggered transfusion, and the threshold was more sensitive for high‐risk patients (<a href="./references#CD006883-bbs2-0004" title="Florentino‐PinedaI , ThompsonGH , Poe‐KochertC , HuangRP , HaberLL , BlakemoreLC . The effect of Amicar in perioperative blood loss in idiopathic scoliosis. The results of a prospective, randomized double‐blind study. Spine2004;29:233‐8. [MEDLINE: 14752343] ThompsonGH , Florentino‐PinedaI , Poe‐KochertC , HaberLL , BlakemoreLC , HuangRP . The effect of Amicar on peri‐operative blood loss in idiopathic scoliosis: report of a prospective, randomised, double blind study. Journal of Bone and Joint Surgery (Proceedings)2005;87:B:295. ">Florentino 2004</a>; <a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>; <a href="./references#CD006883-bbs2-0006" title="KhoshhalK , MukhtarI , ClarkP , JarvisJ , LettsM , SplinterW . Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. Journal of Pediatric Orthopedics2003;23(5):661‐4. [MEDLINE: 12960633] ">Khoshhal 2003</a>); in the fourth study (<a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>), the transfusion trigger was haematocrit ≤ 25% (again with a higher threshold for high‐risk patients). </p> <p>Antifibrinolytic drugs could also decrease mortality through their effect on blood loss. Although no studies reported deaths, the number of children included in our meta‐analysis is very small and precludes any conclusions about drug effects on mortality. Retrospective analysis has estimated mortality rates of 1.3 deaths per 1000 patient cases in the paediatric population undergoing scoliosis surgery, with rates as high as 3.5 deaths per 1000 in those with neuromuscular scoliosis (<a href="./references#CD006883-bbs2-0071" title="SmithJS , SaulleD , ChenCJ , LenkeLG , PollyDWJr , KasliwalMK , et al. Rates and causes of mortality associated with spine surgery based on 108,419 procedures: a review of the Scoliosis Research Society Morbidity and Mortality Database. Spine2012;37:1975‐82. ">Smith 2012</a>). Among these deaths, a minority are estimated to be due to perioperative blood loss. Therefore, it is unlikely that small randomised controlled trials (RCTs) would capture this rare but catastrophic event. </p> <p>Results of our meta‐analysis suggest that aprotinin, tranexamic acid and aminocaproic acid are similarly effective. This assessment was based on the finding that the magnitude of their effects on different outcomes was similar in all included studies. However, the limited number of studies and the paucity of head‐to‐head comparisons in the present systematic review preclude confidence in this assertion. Only one study in our review performed a head‐to‐head analysis of antifibrinolytics (<a href="./references#CD006883-bbs2-0005" title="HalanskiMA , CassidyJA , HetzelS , ReischmannD , HassanN . The efficacy of Amicar versus tranexamic acid in pediatric spinal deformity surgery: a prospective, randomized, double‐blinded pilot study. Spine Deformity2014;2:191‐7. ">Halanski 2014</a>) and reported that the volume of transfused allogeneic blood was greater in those receiving aminocaproic acid than in those receiving tranexamic acid. In addition, as only two studies separately reported the results for secondary scoliosis, this systematic review could not establish whether these antifibrinolytics are more effective for secondary scoliosis than for idiopathic scoliosis, as suggested in the literature. <a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a> reported that tranexamic acid produced a statistically significant reduction in mean blood loss in participants with secondary scoliosis (vs placebo), but not in those with idiopathic scoliosis; however, researchers noted that the small number of participants in each subgroup limits conclusions that can be drawn from this result. </p> </section> <section id="CD006883-sec-0084"> <h4 class="title">Safety</h4> <p>Similarly, the limited number of children exposed to antifibrinolytic drugs does not allow us to determine drug safety. We cannot rule out even frequent serious AEs that may be associated with their use. The safety of antifibrinolytics, especially aprotinin, in adults has been questioned. As noted, evidence suggests that adults undergoing cardiac surgery who are exposed to aprotinin have increased rates of mortality (<a href="./references#CD006883-bbs2-0068" title="RoystonD . The current place of aprotinin in the management of bleeding. Anaesthesia2015;70 (Suppl 1):46‐9. ">Royston 2015</a>). It is unclear whether these concerns apply to children because children do not share the same risk factors as adults for thrombotic events. A cohort study in children who had undergone cardiac surgery found no association between use of aprotinin and acute kidney failure, need for temporary dialysis, neurological complications nor mortality (<a href="./references#CD006883-bbs2-0028" title="BackerCL , KelleAM , StewartRD , SureshSC , AliFN , CohnRA , et al. Aprotinin is safe in pediatric patients undergoing cardiac surgery. Journal of Thoracic and Cardiovascular Surgery2007;134(6):1421‐8. [PUBMED: 18023656] ">Backer 2007</a>). Nonetheless, for now, aprotinin has been suspended from the US market by the US Food and Drug Administration, and evidence of its safety in scoliosis surgery is lacking (<a href="./references#CD006883-bbs2-0042" title="U.S.Food , DrugAdministration . Early communication about an ongoing safety review aprotinin injection (marketed as Trasylol). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070281.htm. Accessed 5 September 2016. ">FDA 2007</a>). </p> </section> </section> <section id="CD006883-sec-0085"> <h3 class="title" id="CD006883-sec-0085">Overall completeness and applicability of evidence</h3> <p>All of our efficacy estimates are based on very small overall numbers of participants and, as our analysis has demonstrated, are susceptible to publication bias. Therefore, the evidence should be considered incomplete for all outcomes. Similarly, owing to the small number of studies and the very small numbers of participants in each study, subgroup analysis based on type of scoliosis or on individual agents was not possible. Therefore, the evidence is insufficient to demonstrate differences in efficacy based on idiopathic versus secondary scoliosis, or for one agent over another. </p> <p>We included studies that administered aprotinin. As discussed, this drug currently is not available in many countries, including the United States, so findings from these studies are not directly applicable to practice in those countries. Similarly, aminocaproic acid is not available in many countries, including most of Europe. </p> </section> <section id="CD006883-sec-0086"> <h3 class="title" id="CD006883-sec-0086">Quality of the evidence</h3> <p>As with all quantitative systematic reviews, meta‐analyses are only as good as the data reported in each study. Efficacy data were reported differently across studies, and safety data were inadequately assessed or presented. </p> <p>When assessing the quality of findings using GRADE, we ranked quality from low to very low across the different efficacy outcomes. Low rankings were primarily due to inconsistency (unexplained heterogeneity), imprecision (small sample sizes, few events, wide confidence intervals), or susceptibility to the impact of publication bias. All studies enrolled fewer than 50 participants in each arm, with an average of only 51 participants in total across studies. Small studies are likely underpowered to detect statistical differences in what may be clinically relevant effects (<a href="./references#CD006883-bbs2-0039" title="DerryS , MooreRA . Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD004233.pub4] ">Derry 2012</a>). As previously stated, our analyses of AEs are likely underpowered to detect notable differences, and they do not capture rare but potentially catastrophic events. </p> </section> <section id="CD006883-sec-0087"> <h3 class="title" id="CD006883-sec-0087">Potential biases in the review process</h3> <p>We restricted this review to randomized studies, thus limiting the potential for bias. Possible sources of bias that could have affected the validity of the review include the following. </p> <p> <ul id="CD006883-list-0008"> <li> <p>Combination of studies from different surgical populations. We planned to conduct a subgroup analysis according to whether participants had idiopathic or secondary scoliosis; however, only four studies enrolled patients with secondary scoliosis, and only two of these reported data separately for each diagnosis. </p> </li> <li> <p>Inclusion of studies with different dosing regimens in the same analysis. Analyses of total blood loss and total blood transfused show that participants lost approximately twice as much blood and required twice the volume of blood in transfusion when a low‐dose regimen of tranexamic acid (<a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>) was indirectly compared with a high‐dose regimen (<a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>). However, these studies reported similar differences between placebo groups, suggesting that this finding may reflect a difference in study methods, rather than being due to a difference in dosing regimens. The very limited data preclude separate analyses based on dose regimens. </p> </li> <li> <p>A fixed‐effect model for statistical analysis. As stated in the Results section, the point estimate and 95% confidence interval (CI) for our primary analysis remained unchanged when a random‐effects model was applied. Although secondary analyses became statistically insignificant when a random‐effects model was used, this may reflect the small number of studies and the marginal statistical significance noted when a fixed‐effect model was used, rather than a fundamental flaw in our method of analysis. </p> </li> <li> <p>Possibility of publication bias (unpublished trials showing no benefit of antifibrinolytics over placebo). We attempted to limit this risk by searching the clinical trials registry http://www.clinicaltrials.gov. As previously mentioned, to assess the possible impact of publication bias, we calculated the number of additional participants needed in studies with zero effect to change the number needed to treat for an additional beneficial outcome (NNTB) to 10, which we considered the threshold for a clinically meaningful effect. All analyses of dichotomous outcomes were shown to be susceptible; therefore we cannot rule out the possibility that publication bias may have affected our findings. </p> </li> <li> <p>Nature of analyses. Few manuscripts stated whether analyses were performed on intention‐to‐treat (ITT) or per‐protocol populations, and those that stated this did not describe imputation methods used. However, given the short duration of the time period of interest, dropouts were few, if any, in most of these studies. </p> </li> </ul> </p> </section> <section id="CD006883-sec-0088"> <h3 class="title" id="CD006883-sec-0088">Agreements and disagreements with other studies or reviews</h3> <p>A previous systematic review that evaluated the effect of aprotinin on children undergoing cardiac surgery found that aprotinin reduced the risk of transfusion (<a href="./references#CD006883-bbs2-0027" title="ArnoldDM , FergussonDA , ChanA , CookR , FraserG , LimW , et al. Avoiding transfusions in children undergoing cardiac surgery: a meta‐analysis of randomized trials of aprotinin. Anesthesia and Analgesia2006;102:731‐7. [MEDLINE: 16492820] ">Arnold 2006</a>). We were able to demonstrate such a beneficial effect in reducing allogeneic but not overall blood transfusion requirements in our meta‐analysis for children undergoing scoliosis surgery. This may be explained in part by the fact that in our review, only one small study enrolling 43 participants reported this outcome for aprotinin compared with data for 626 participants in Arnold's analysis. The 2006 review also found no serious AEs but, in common with our review, the sample size was small. Therefore, we can draw no conclusions about the safety of aprotinin in children. </p> <p>A 2011 Cochrane review that analyzed the efficacy of antifibrinolytics for minimising perioperative allogeneic blood transfusion across all surgeries in adult populations demonstrated that aprotinin was slightly more effective than tranexamic acid and aminocaproic acid in reducing blood loss and receipt of blood transfusion, but with an inferior safety profile (<a href="./references#CD006883-bbs2-0048" title="HenryDA , CarlessPA , MoxeyAJ , O’ConnellD , StokesBJ , FergussonDA , et al. Anti‐fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD001886.pub4] ">Henry 2011</a>). All antifibrinolytics were superior to placebo in reducing blood loss and the need for transfusion. </p> <p>A recent systematic review of antifibrinolytic agents in children undergoing non‐cardiac surgery included not only RCTs, but also retrospective studies and data from other meta‐analyses (<a href="./references#CD006883-bbs2-0041" title="FaraoniD , GoobieSM . The efficacy of antifibrinolytic drugs in children undergoing noncardiac surgery: a systematic review of the literature. Anesthesia and Analgesia2014;118:628‐36. ">Faraoni 2014</a>). This 2014 review excluded studies assessing aprotinin because of its limited availability worldwide. Although meta‐analysis was not performed, and despite its more relaxed inclusion criteria, findings of limited evidence to support reduced blood loss and transfusion requirements in the <a href="./references#CD006883-bbs2-0041" title="FaraoniD , GoobieSM . The efficacy of antifibrinolytic drugs in children undergoing noncardiac surgery: a systematic review of the literature. Anesthesia and Analgesia2014;118:628‐36. ">Faraoni 2014</a> review were similar to ours. In addition to the limitations in evidence already discussed, review authors highlighted the lack of pharmacokinetic studies of antifibrinolytics in this population, which in part may account for the large variability in dosing regimens employed. <a href="./references#CD006883-bbs2-0041" title="FaraoniD , GoobieSM . The efficacy of antifibrinolytic drugs in children undergoing noncardiac surgery: a systematic review of the literature. Anesthesia and Analgesia2014;118:628‐36. ">Faraoni 2014</a> mentioned that tranexamic acid is associated with increased risk of seizures in children undergoing cardiac surgery. Neither <a href="./references#CD006883-bbs2-0041" title="FaraoniD , GoobieSM . The efficacy of antifibrinolytic drugs in children undergoing noncardiac surgery: a systematic review of the literature. Anesthesia and Analgesia2014;118:628‐36. ">Faraoni 2014</a> nor our review found reports of seizures in included studies. </p> <p>A systematic review and meta‐analysis of the use of tranexamic acid included all types of spinal surgery (i.e. not only scoliosis) (<a href="./references#CD006883-bbs2-0080" title="YangB , LiH , WangD , HeX , ZhangC , YangP . Systematic review and meta‐analysis of perioperative intravenous tranexamic acid use in spinal surgery. PLoS ONE2013;8:e55436. ">Yang 2013</a>). It included the two studies of tranexamic acid in scoliosis surgery that were included in our review (<a href="./references#CD006883-bbs2-0008" title="NeilipovitzD , MurtoK , HallL , BarrowmanN , SplinterW . A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesthesia and Analgesia2001;93:82‐7. [MEDLINE: 151277250] ">Neilipovitz 2001</a>; <a href="./references#CD006883-bbs2-0009" title="SethnaNF , ZurakowskiD , BrustowiczM , BacsikJ , SullivanL , ShapiroF . Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. Anesthesiology2005;102(4):727‐32. [MEDLINE: 15791100] ">Sethna 2005</a>) and found reductions in blood loss and transfusion requirements, with no differences in safety between tranexamic acid and placebo. Of note, in contrast to our review, <a href="./references#CD006883-bbs2-0080" title="YangB , LiH , WangD , HeX , ZhangC , YangP . Systematic review and meta‐analysis of perioperative intravenous tranexamic acid use in spinal surgery. PLoS ONE2013;8:e55436. ">Yang 2013</a> systematic review assessed both of the above studies as having low risk of bias for all outcomes, despite apparently using the same criteria for assessment. This may reflect the subjective nature of such assessments. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006883-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006883-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006883-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006883-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Mean total blood loss (mL), outcome: 1.1 Antifibrinolytics versus placebo." data-id="CD006883-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Mean total blood loss (mL), outcome: 1.1 Antifibrinolytics versus placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Number of participants receiving blood transfusion, outcome: 2.1 Antifibrinolytics versus placebo." data-id="CD006883-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Number of participants receiving blood transfusion, outcome: 2.1 Antifibrinolytics versus placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 Mean total blood transfused (mL), outcome: 4.1 Antifibrinolytics versus placebo." data-id="CD006883-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 Mean total blood transfused (mL), outcome: 4.1 Antifibrinolytics versus placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mean total blood loss (mL), Outcome 1 Antifibrinolytics vs placebo." data-id="CD006883-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Mean total blood loss (mL), Outcome 1 Antifibrinolytics vs placebo.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Mean total blood loss (mL), Outcome 2 Antifibrinolytic vs antifibrinolytic." data-id="CD006883-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Mean total blood loss (mL), Outcome 2 Antifibrinolytic vs antifibrinolytic.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Number of participants receiving blood transfusion, Outcome 1 Antifibrinolytics vs placebo." data-id="CD006883-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Number of participants receiving blood transfusion, Outcome 1 Antifibrinolytics vs placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Number of participants receiving blood transfusion with allogeneic blood, Outcome 1 Antifibrinolytics vs placebo." data-id="CD006883-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Number of participants receiving blood transfusion with allogeneic blood, Outcome 1 Antifibrinolytics vs placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Number of participants receiving blood transfusion with allogeneic blood, Outcome 2 Antifibrinolytic vs antifibrinolytic." data-id="CD006883-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Number of participants receiving blood transfusion with allogeneic blood, Outcome 2 Antifibrinolytic vs antifibrinolytic. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-004-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mean total blood transfused (mL), Outcome 1 Antifibrinolytics vs placebo." data-id="CD006883-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Mean total blood transfused (mL), Outcome 1 Antifibrinolytics vs placebo.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Number of deaths, Outcome 1 Antifibrinolytics vs placebo." data-id="CD006883-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Number of deaths, Outcome 1 Antifibrinolytics vs placebo.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Number of deaths, Outcome 2 Antifibrinolytic vs antifibrinolytic." data-id="CD006883-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Number of deaths, Outcome 2 Antifibrinolytic vs antifibrinolytic.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Number of participants reporting any adverse event, Outcome 1 Antifibrinolytics vs placebo." data-id="CD006883-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Number of participants reporting any adverse event, Outcome 1 Antifibrinolytics vs placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Number of participants reporting any adverse event, Outcome 2 Antifibrinolytic vs antifibrinolytic." data-id="CD006883-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Number of participants reporting any adverse event, Outcome 2 Antifibrinolytic vs antifibrinolytic. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Number of participants experiencing a serious adverse event, Outcome 1 Antifibrinolytics vs placebo." data-id="CD006883-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Number of participants experiencing a serious adverse event, Outcome 1 Antifibrinolytics vs placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Number of participants experiencing a serious adverse event, Outcome 2 Antifibrinolytic vs antifibrinolytic." data-id="CD006883-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Number of participants experiencing a serious adverse event, Outcome 2 Antifibrinolytic vs antifibrinolytic. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Number of participants withdrawing owing to adverse events, Outcome 1 Antifibrinolytics vs placebo." data-id="CD006883-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Number of participants withdrawing owing to adverse events, Outcome 1 Antifibrinolytics vs placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Number of participants withdrawing owing to adverse events, Outcome 2 Antifibrinolytic vs antifibrinolytic." data-id="CD006883-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Number of participants withdrawing owing to adverse events, Outcome 2 Antifibrinolytic vs antifibrinolytic. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Number of participants experiencing renal insufficiency, Outcome 1 Antifibrinolytics vs placebo." data-id="CD006883-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Number of participants experiencing renal insufficiency, Outcome 1 Antifibrinolytics vs placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Number of participants experiencing renal insufficiency, Outcome 2 Antifibrinolytic vs antifibrinolytic." data-id="CD006883-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Number of participants experiencing renal insufficiency, Outcome 2 Antifibrinolytic vs antifibrinolytic. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Number of participants experiencing thrombotic events, Outcome 1 Antifibrinolytics vs placebo." data-id="CD006883-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Number of participants experiencing thrombotic events, Outcome 1 Antifibrinolytics vs placebo. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006883-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/urn:x-wiley:14651858:media:CD006883:CD006883-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_t/tCD006883-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Number of participants experiencing thrombotic events, Outcome 2 Antifibrinolytic vs antifibrinolytic." data-id="CD006883-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Number of participants experiencing thrombotic events, Outcome 2 Antifibrinolytic vs antifibrinolytic. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/media/CDSR/CD006883/image_n/nCD006883-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006883-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Mean total blood loss (mL)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antifibrinolytics compared with placebo or each other for children undergoing surgery for scoliosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children undergoing surgery for scoliosis<br/> <b>Settings:</b> children's hospitals in the USA and Canada<br/> <b>Intervention:</b> antifibrinolytics<br/> <b>Comparison:</b> placebo or each other </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo or each other</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood loss (mL: antifibrinolytics vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood loss (mL): antifibrinolytics vs placebo in the intervention groups was<br/> <b>426.56 lower</b> <br/> (602.59 to 250.53 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood loss (mL): aminocaproic acid vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood loss (mL): aminocaproic acid vs placebo in the intervention groups was<br/> <b>325 lower</b> <br/> (586.83 to 63.17 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood loss (mL): aprotinin vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood loss (mL): aprotinin vs placebo in the intervention groups was<br/> <b>450.41 lower</b> <br/> (726.64 to 174.19 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood loss (mL): tranexamic acid vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood loss (mL): tranexamic acid vs placebo in the intervention groups was<br/> <b>681.81 lower</b> <br/> (1149.12 to 214.49 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood loss (mL): aminocaproic acid vs tranexamic acid</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood loss (mL): aminocaproic acid vs tranexamic acid in the intervention groups was<br/> <b>463 higher</b> <br/> (155.22 lower to 1081.22 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI = confidence interval. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Unclear or high risk of bias in &gt; 1 domain for each study.<br/> <sup>b</sup>Total population size is less than 400.<br/> <sup>c</sup>Wide confidence interval, which includes no effect AND appreciable harm. </p> <p>Quality of evidence downgraded by two levels for all outcomes.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Mean total blood loss (mL)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006883-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Number of participants receiving blood transfusion</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antifibrinolytics compared with placebo for children undergoing surgery for scoliosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children undergoing surgery for scoliosis<br/> <b>Settings:</b> children's hospitals in the USA and Canada<br/> <b>Intervention:</b> antifibrinolytics<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants receiving blood transfusion: antifibrinolytics vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.65</b> <br/> (0.5 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>195<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>602 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>391 per 1000</b> <br/> (301 to 512) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>464 per 1000</b> <br/> (357 to 607) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants receiving blood transfusion: aminocaproic acid vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.48</b> <br/> (0.3 to 0.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>108<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>490 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>235 per 1000</b> <br/> (147 to 372) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>554 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>266 per 1000</b> <br/> (166 to 421) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants receiving blood transfusion: aprotinin vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.75</b> <br/> (0.44 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>43<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a,b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>536 per 1000</b> <br/> (314 to 907) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>536 per 1000</b> <br/> (314 to 907) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants receiving blood transfusion: tranexamic acid vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.85</b> <br/> (0.56 to 1.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>44<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a,b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>607 per 1000</b> <br/> (400 to 929) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>607 per 1000</b> <br/> (400 to 928) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI = confidence interval; RR = risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Unclear or high risk of bias for &gt; 1 domain for each study.<br/> <sup>b</sup>Total number of events is less than 300.<br/> <sup>c</sup>Susceptible to publication bias.<br/> <sup>d</sup>Large differences in effect between studies.<br/> <sup>e</sup>Wide confidence interval, which includes no effect AND benefit. </p> <p>Quality of evidence downgraded by three levels for all outcomes.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Number of participants receiving blood transfusion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006883-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Number of participants receiving transfusion with allogeneic blood</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antifibrinolytics compared with placebo for children undergoing surgery for scoliosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children undergoing surgery for scoliosis<br/> <b>Settings:</b> children's hospitals in the USA and Canada<br/> <b>Intervention:</b> antifibrinolytics<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants receiving transfusion with allogeneic blood: antifibrinolytics vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.11</b> <br/> (0.01 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>79<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> <br/> (2 to 308) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> <br/> (1 to 247) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants receiving transfusion with allogeneic blood: aminocaproic acid vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative risk not estimable as no events occurred in either group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Number of participants receiving transfusion with allogeneic blood: aprotinin vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.11</b> <br/> (0.01 to 1.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>43<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> <br/> (3 to 494) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> <br/> (3 to 495) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI = confidence interval; RR = risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Unclear or high risk of bias for &gt; 1 domain for each study.<br/> <sup>b</sup>Unexplained heterogeneity.<br/> <sup>c</sup>Total number of events is less than 300.<br/> <sup>d</sup>Wide confidence interval, which includes no effect AND benefit. </p> <p>Quality of evidence downgraded by three levels for all outcomes.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Number of participants receiving transfusion with allogeneic blood</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006883-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Mean total volume of blood transfused (mL)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Antifibrinolytics compared with placebo for children undergoing surgery for scoliosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children undergoing surgery for scoliosis<br/> <b>Settings:</b> children's hospitals in the USA and Canada<br/> <b>Intervention:</b> antifibrinolytics<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Antifibrinolytics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood transfused (mL): antifibrinolytics vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood transfused (mL): antifibrinolytics vs placebo in the intervention groups was<br/> <b>327.41 lower</b> <br/> (469.04 to 185.78 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood transfused (mL): aminocaproic acid vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood transfused (mL): aminocaproic acid vs placebo in the intervention groups was<br/> <b>245 lower</b> <br/> (481.03 to 8.97 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood transfused (mL): aprotinin vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood transfused (mL): aprotinin vs placebo in the intervention groups was<br/> <b>361.42 lower</b> <br/> (583.88 to 138.96 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean total blood transfused (mL): tranexamic acid vs placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean total blood transfused (mL): tranexamic acid vs placebo in the intervention groups was<br/> <b>395.14 lower</b> <br/> (687.55 to 102.73 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI = confidence interval. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Unclear risk of bias for &gt; 1 domain in most studies<br/> <sup>b</sup>Total population size is less than 400 </p> <p>Quality of evidence downgraded by two levels for all outcomes</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Mean total volume of blood transfused (mL)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/full#CD006883-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006883-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mean total blood loss (mL)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Antifibrinolytics vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐426.56 [‐602.59, ‐250.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Aminocaproic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐325.0 [‐586.83, ‐63.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Aprotinin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐450.41 [‐726.64, ‐174.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐681.81 [‐1149.12, ‐214.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Antifibrinolytic vs antifibrinolytic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>463.0 [‐155.22, 1081.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Aminocaproic acid vs tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>463.0 [‐155.22, 1081.22]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mean total blood loss (mL)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006883-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Number of participants receiving blood transfusion</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Antifibrinolytics vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.50, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Aminocaproic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.30, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Aprotinin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.44, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.56, 1.30]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Number of participants receiving blood transfusion</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006883-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Number of participants receiving blood transfusion with allogeneic blood</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Antifibrinolytics vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Aminocaproic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Aprotinin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Antifibrinolytic vs antifibrinolytic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.40, 5.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Number of participants receiving blood transfusion with allogeneic blood</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006883-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mean total blood transfused (mL)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Antifibrinolytics vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐327.41 [‐469.04, ‐185.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Aminocaproic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐245.00 [‐481.03, ‐8.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Aprotinin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐361.42 [‐583.88, ‐138.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐395.14 [‐687.55, ‐102.73]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mean total blood transfused (mL)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006883-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Number of deaths</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Antifibrinolytics vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Aminocaproic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Aprotinin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Antifibrinolytic vs antifibrinolytic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Aminocaproic acid vs tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Number of deaths</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006883-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Number of participants reporting any adverse event</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Antifibrinolytics vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Aprotinin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Antifibrinolytic vs antifibrinolytic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 6.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Aminocaproic acid vs tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 6.89]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Number of participants reporting any adverse event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006883-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Number of participants experiencing a serious adverse event</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Antifibrinolytics vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Aminocaproic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Aprotinin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Antifibrinolytic vs antifibrinolytic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Aminocaproic acid vs tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Number of participants experiencing a serious adverse event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006883-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Number of participants withdrawing owing to adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Antifibrinolytics vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Aminocaproic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Aprotinin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Antifibrinolytic vs antifibrinolytic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Aminocaproic acid vs tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Number of participants withdrawing owing to adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006883-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Number of participants experiencing renal insufficiency</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Antifibrinolytics vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Aminocaproic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Aprotinin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Antifibrinolytic vs antifibrinolytic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Aminocaproic acid vs tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Number of participants experiencing renal insufficiency</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006883-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Number of participants experiencing thrombotic events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Antifibrinolytics vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 2.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Aminocaproic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Aprotinin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Antifibrinolytic vs antifibrinolytic <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Aminocaproic acid vs tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Number of participants experiencing thrombotic events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006883.pub3/references#CD006883-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006883.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006883-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006883-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006883-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="pl#CD006883-note-0002">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD006883-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006883\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006883\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006883\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006883\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006883\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tkZQC4GK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006883.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006883.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006883.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006883.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006883.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716521875"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006883.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716521879"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006883.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da19058ed9379',t:'MTc0MDcxNjUyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 